Feline Morbillivirus

Overview and Taxonomy of Feline Morbillivirus

Discovery and Initial Characterization

Feline morbillivirus (FeMV) was first isolated in 2012 from stray cats in Hong Kong, representing a seminal discovery in feline virology that has since catalyzed a global research effort [1, 2, 3, 4, 5]. The initial identification emerged from investigations into cats presenting with urinary tract disease, and subsequent molecular and phylogenetic analyses definitively placed this novel agent within the genus Morbillivirus of the family Paramyxoviridae, subfamily Orthoparamyxovirinae [3, 4, 5]. This taxonomic assignment was initially surprising given that FeMV exhibited several biological characteristics that diverged significantly from the classical morbilliviruses, including measles virus (MeV), canine distemper virus (CDV), rinderpest virus (RPV), and peste des petits ruminants virus (PPRV) [5, 6, 7]. The discovery of FeMV expanded the known host range and ecological niche of morbilliviruses, introducing a pathogen that primarily targets feline species and demonstrates a unique tropism for renal tissues [2, 3, 4].

The initial isolation and subsequent genomic characterization revealed that FeMV possesses a single-stranded, negative-sense RNA genome approximately 16 kilobases in length, consistent with the genome organization of other paramyxoviruses [3, 5]. The genome encodes six structural proteins in the canonical order: nucleocapsid (N), phosphoprotein (P/V/C), matrix (M), fusion (F), hemagglutinin (H), and large polymerase (L) proteins [3, 8]. Notably, the P gene exhibits the highest degree of polymorphism among FeMV strains, a feature that has implications for genetic diversity and potential immune evasion [8]. This genomic architecture, while broadly conserved within the genus, harbors specific variations that underpin the virus's distinctive biology, including its apparent reliance on cathepsin-dependent proteolytic processing of the fusion protein, a trait that distinguishes FeMV from other morbilliviruses that typically utilize furin [7].

Taxonomic Position and Phylogenetic Relationships

FeMV is classified as the seventh established species within the genus Morbillivirus, alongside MeV, CDV, RPV, PPRV, phocine distemper virus (PDV), and cetacean morbillivirus (CeMV) [6, 9]. However, phylogenetic analyses consistently demonstrate that FeMV occupies a deeply divergent branch within the genus, forming a distinct lineage that is separate from the clade comprising the classical SLAM-using morbilliviruses [6, 7]. This evolutionary distance is reflected at the genomic level, with FeMV sharing only approximately 78% nucleotide homology with other known feline morbilliviruses when comparing distinct genotypes, and even lower homology with non-feline morbilliviruses [10]. The profound genetic divergence between FeMV and its closest relatives suggests a long evolutionary separation, potentially indicating that FeMV represents an ancient lineage that has adapted uniquely to its feline host [6, 7].

Comparative sequence analysis of morbillivirus receptors provides critical context for understanding FeMV's taxonomic and biological uniqueness. The classical morbilliviruses universally utilize signaling lymphocytic activation molecule F1 (SLAMF1, also known as CD150) as a primary receptor on immune cells and nectin-4 as an epithelial receptor [6, 11, 12]. While FeMV has been confirmed to use feline SLAMF1 as a cellular receptor, compelling evidence indicates that its receptor-binding domain is uniquely adapted to the feline ortholog of this protein, exhibiting minimal cross-reactivity with SLAMF1 from other species [13, 7]. Furthermore, the hemagglutinin protein of FeMV displays antigenic distinctiveness, as sera from FeMV-infected cats contain high titers of neutralizing antibodies that fail to cross-neutralize other morbilliviruses, and conversely, antibodies against other morbilliviruses do not neutralize FeMV [13]. This antigenic isolation is a hallmark of FeMV's taxonomic position and suggests that its surface glycoproteins have evolved under different selective pressures compared to those of classical morbilliviruses [13, 6].

Genetic Diversity and Genotype Classification

The genetic diversity of FeMV is extensive and has led to the classification of at least two major genotypes, designated FeMV genotype 1 (FeMV-1) and FeMV genotype 2 (FeMV-2) [2, 10, 3, 14, 5, 15]. FeMV-1 is the most widely distributed genotype and has been further subdivided into several subclusters, including FeMV-1A and FeMV-1B, based on phylogenetic analysis of partial or complete genomic sequences [14, 16, 17]. FeMV-1 strains have been detected in domestic cats across a broad geographic range, including Hong Kong, Japan, China, Thailand, Malaysia, Italy, Germany, the United Kingdom, the United States, Brazil, and Chile, among others [3, 9, 11, 12, 15, 20, 21, 23-25, 34, 36, 39]. The FeMV-1A subcluster appears to be particularly prevalent in Asian countries, with Thai strains, for example, exhibiting up to 98.5% nucleotide identity with one another within this clade [14]. In contrast, FeMV-1B has been identified in European populations, including strains from northwestern Italy and Germany, suggesting a geographic segregation of sub-genotypes [16, 18].

The second major genotype, FeMV-2, was initially isolated from the urine of cats with urinary tract diseases and displays approximately 78% nucleotide homology to FeMV-1, indicating a substantial genetic distance that justifies its classification as a distinct genotype [10]. FeMV-2 has been identified in domestic cats in various regions, including Germany and Japan, and serological evidence suggests its circulation in cat populations in Chile [10, 19]. The genetic diversity among FeMV strains is further complicated by the detection of natural recombination events. One landmark study identified a Japanese FeMV strain, MiJP003, as a probable recombinant between two distinct viral lineages originating from Japan and Hong Kong, with the recombination breakpoints localized within the F and H genes [8]. This observation underscores the capacity for genetic exchange among FeMV strains and highlights the dynamic nature of FeMV evolution, which may contribute to the emergence of novel variants with altered biological properties [8]. Additionally, the phosphoprotein (P) gene appears to be under positive selection in FeMV-1, whereas the genome as a whole is predominantly subject to negative (purifying) selection, suggesting that adaptive evolution may be concentrated in specific genomic regions [14].

Host Range and Cross-Species Transmission

While FeMV was initially considered a pathogen exclusive to domestic cats (Felis catus), accumulating evidence has substantially expanded the known host range of this virus, with implications for both veterinary medicine and wildlife conservation [2, 20, 21, 22, 23]. The detection of FeMV-1 in dogs with respiratory diseases represents a significant milestone, as it demonstrates the ability of this virus to infect non-felid hosts [20]. In a study of dogs with respiratory illness, FeMV-1 RNA was detected in 12.4% of animals, and viral antigen was confirmed in lung tissues via immunohistochemistry, with viral isolation achieved from affected dogs [20]. This finding not only expands the known tropism of FeMV but also raises concerns about the potential for cross-species transmission between domestic cats and dogs, particularly in environments where these animals coexist.

Beyond domestic canids, FeMV has also been detected in wild felid species, including black leopards (Panthera pardus) in Thailand and guignas (Leopardus guigna) in Chile [22, 23]. In black leopards, FeMV-1 infection was associated with severe azotemia and tubulointerstitial nephritis, mirroring the pathological findings observed in domestic cats [22]. The detection of FeMV-specific antibodies and viral RNA in guignas, a wild felid species endemic to South America, further underscores the susceptibility of non-domestic felids to FeMV infection [23]. These findings are consistent with broader patterns of morbillivirus ecology, wherein closely related species within the family Felidae can serve as susceptible hosts for various morbilliviruses, including CDV [24].

Perhaps the most remarkable expansion of the FeMV host range is the detection of FeMV RNA associated with pathological and immunohistochemical findings in white-eared opossums (Didelphis albiventris), a synanthropic marsupial species inhabiting peri-urban areas of Brazil [21]. In these opossums, FeMV was detected in lung and kidney tissues, and the virus was successfully isolated in Crandell Rees feline kidney cells, resulting in syncytia formation and cell death [21]. This finding has profound ecological and epidemiological implications, as it suggests that marsupials, which are phylogenetically distant from placental carnivores, can serve as competent hosts for FeMV and potentially act as reservoirs or bridging hosts for virus transmission between wildlife and domestic animal populations [21]. The ability of FeMV to infect such a diverse array of hosts, ranging from marsupials to carnivores, indicates a broader receptor usage or adaptive capacity than initially appreciated, although in vitro studies suggest that FeMV infects only cell lines derived from cats and African green monkeys, with no infectivity observed in human cell lines [25]. This latter observation, while reassuring from a zoonotic perspective, does not preclude the possibility that FeMV could acquire the ability to infect human cells through adaptive mutations, a scenario that warrants ongoing surveillance [25, 6].

Ecological and Epidemiological Context

The global distribution of FeMV, as evidenced by its detection in Asia, Europe, North America, South America, Africa, and Oceania, attests to its successful establishment in feline populations worldwide [2, 3, 4, 26]. Prevalence rates vary markedly depending on the population studied, the detection methodology employed, and the type of biological sample analyzed. For instance, FeMV RNA detection rates in urine samples range from 7.3% in northwestern Italy to 16.1% in southern Italy, while seroprevalence rates can exceed 60% in some populations [27, 16, 19]. In Japan, a study of cats with suspected acute viral infections detected FeMV RNA in 31.4% of blood samples, highlighting the potential for FeMV to be associated with acute febrile illness [28]. These variable prevalence estimates reflect the complex epidemiology of FeMV, which is influenced by factors such as age, housing conditions (shelter versus household), geographic location, and co-infections with other pathogens, including feline retroviruses [27, 14].

The transmission dynamics of FeMV remain incompletely understood, but the consistent detection of high viral loads in urine compared to other tissues, coupled with prolonged viral shedding in urine lasting up to 360 days in some cases, strongly suggests that urine is a primary route of viral excretion and transmission [2, 29, 27, 30]. The presence of FeMV antigen in renal tubular epithelial cells, as demonstrated by immunohistochemistry and in situ hybridization, supports the hypothesis that the kidney serves as a major site of viral replication, with virions shed into the urine [31, 32, 33]. Environmental persistence of FeMV may be facilitated by the virus's notable stability at 4°C, where it retains high titers for at least 12 days, although it is rapidly inactivated at temperatures above 60°C [34]. The ability of FeMV to infect CD4+ T cells, CD20+ B cells, and monocytes in peripheral blood mononuclear cells suggests that viremia and lymphoid tropism contribute to systemic dissemination and potentially to the establishment of persistent infections [10]. Indeed, longitudinal studies have documented persistent viral shedding in urine despite the presence of neutralizing antibodies, indicating that FeMV can evade immune clearance and establish chronic infections [10, 29, 30]. This capacity for persistence, a hallmark of some paramyxoviruses, is thought to be a key factor in the pathogenesis of FeMV-associated renal disease, as chronic viral replication may drive ongoing tissue damage and inflammation [31, 2, 29].

Molecular Virology and Genomic Organization

Taxonomic Classification and Phylogenetic Position

Feline morbillivirus (FeMV) is classified within the genus Morbillivirus, family Paramyxoviridae, subfamily Orthoparamyxovirinae. This taxonomic assignment, however, belies a profound molecular divergence that positions FeMV as a highly unusual and phylogenetically distinct member of the genus. While the canonical morbilliviruses, including measles virus (MeV), canine distemper virus (CDV), rinderpest virus (RPV), peste des petits ruminants virus (PPRV), phocine distemper virus (PDV), and cetacean morbillivirus (CeMV), form a tightly clustered clade characterized by high virulence, systemic disease, and utilization of SLAMF1 (CD150) and nectin-4 as cellular receptors, FeMV occupies an isolated branch that suggests a fundamentally different evolutionary trajectory [5, 6, 7]. Molecular phylogenetic analyses consistently demonstrate that FeMV is the most divergent member of the genus, sharing only approximately 78% nucleotide homology with other morbilliviruses at the whole-genome level [10]. This genetic distance is comparable to the divergence observed between distinct morbillivirus species, yet FeMV retains sufficient genomic organizational features to justify its inclusion within the genus. The discovery of additional novel morbilliviruses in rodents, bats, and swine has further complicated the phylogenetic landscape, revealing that FeMV may represent an intermediate evolutionary form between the classical, highly pathogenic morbilliviruses and these newly identified, ecologically distinct lineages [6, 9]. Indeed, the porcine morbillivirus (PoMV) recently identified in cases of fetal death and encephalitis in swine shows closest genetic affinity to CDV (62.9% nucleotide identity) rather than FeMV, underscoring the remarkable diversity within the genus [9].

Genome Architecture and Organization

The FeMV genome is a non-segmented, single-stranded, negative-sense RNA molecule of approximately 16.5 kilobases, conforming to the typical paramyxovirus gene order: 3′-N-P/V/C-M-F-H-L-5′ [8, 7]. This canonical arrangement encodes six structural proteins: the nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the fusion glycoprotein (F), the hemagglutinin protein (H), and the large polymerase protein (L). The P gene exhibits a remarkable capacity for transcriptional editing, giving rise to additional accessory proteins, V and C, through a co-transcriptional RNA editing mechanism involving the insertion of one or two non-templated guanine residues at a conserved editing site [8]. This phenomenon is a hallmark of morbilliviruses and paramyxoviruses more broadly, enabling a single genomic locus to generate multiple polypeptide products with distinct functional roles. The V protein, in particular, is known to function as an interferon antagonist in other morbilliviruses, and its presence in FeMV is inferred to play a similar role in subverting host innate immune responses, although direct experimental confirmation in FeMV remains limited.

Among the six genes, the P gene exhibits the highest degree of nucleotide and predicted amino acid sequence polymorphism across FeMV strains, a feature that has been exploited for phylogenetic analyses and molecular epidemiological studies [8]. In contrast, the N gene contains regions of striking conservation, including a stretch of identical amino acid residues shared across diverse morbilliviruses, which likely reflects functional constraints essential for nucleocapsid assembly and RNA binding [35]. This conservation is sufficiently high to permit antigenic cross-reactivity between the N proteins of FeMV and CDV, a finding with substantial implications for serological diagnostics [1]. Conversely, the H and F glycoprotein genes display significant heterogeneity, particularly in the context of recombination events that have shaped the evolutionary history of certain FeMV lineages [8]. Selective pressure analysis of FeMV-1 genomes has revealed that the virus is primarily subject to negative (purifying) selection, indicating strong functional constraints on most coding regions. However, positively selected sites have been identified more frequently within the phosphoprotein gene, suggesting that immune-driven adaptation may target this region specifically [14].

Receptor Usage and Viral Entry

One of the most distinctive molecular features of FeMV is its receptor usage profile. The classical morbilliviruses, MeV, CDV, RPV, PPRV, PDV, and CeMV, all utilize SLAMF1 (CD150) as a principal entry receptor on immune cells and nectin-4 (PVRL4) as the receptor mediating epithelial cell infection and viral shedding. These viruses exhibit a high degree of cross-species receptor compatibility; for instance, CDV can use SLAMF1 from multiple carnivore species, enabling its remarkably broad host range that spans virtually the entire order Carnivora and extends to non-human primates [11, 24, 12]. FeMV, by contrast, appears to employ a receptor usage strategy that is both more restricted and, paradoxically, more permissive in certain contexts. Experimental evidence has firmly established that FeMV uses feline SLAMF1 (CD150) as a cellular receptor, a finding confirmed through multiple independent approaches including cell-cell fusion assays, infection blockade with anti-SLAMF1 antibodies, and the demonstration that Vero cells stably expressing feline SLAMF1 support robust FeMV replication [29, 13, 7]. However, unlike other morbilliviruses that can utilize SLAMF1 orthologs from multiple species, FeMV demonstrates strict specificity for the feline SLAMF1 protein; it cannot use SLAMF1 from other species tested, and conversely, non-feline morbilliviruses cannot efficiently use feline SLAMF1 as a receptor [13]. This receptor specificity likely imposes a significant constraint on the host range of FeMV, potentially limiting natural infection to felids and closely related species.

The structural basis for this restricted receptor usage resides in the hemagglutinin (H) protein, which mediates attachment to SLAMF1. Comparative sequence analysis of the receptor-binding domain of FeMV H reveals unique amino acid differences compared to the conserved binding interface of other morbilliviruses, particularly at residues critical for SLAMF1 interaction [6, 11]. Feline SLAMF1 itself harbors significant amino acid changes in its V-set immunoglobulin domain (the morbillivirus-binding region) relative to canine, ruminant, and human SLAMF1, providing a molecular explanation for the species-specific compatibility [11]. Importantly, the use of feline SLAMF1 as a receptor aligns with the lymphotropism of FeMV observed in vivo; viral antigen has been detected in lymphocytes within the spleen, lymph nodes, and inflammatory infiltrates in the kidney, and experimental infections have confirmed that FeMV can infect CD4+ T cells, CD20+ B cells, and monocytes in primary peripheral blood mononuclear cell cultures [10, 32, 22].

Fusion Glycoprotein Processing and Cathepsin Dependence

Perhaps the most remarkable molecular peculiarity of FeMV lies in its fusion glycoprotein (F protein) processing mechanism. For all other known morbilliviruses, the F protein is cleaved from its inactive precursor (F0) into the fusion-competent form (F1+F2) by the host protease furin, a ubiquitous cellular enzyme that operates in the trans-Golgi network. This furin-dependent cleavage is a hallmark of the genus and is essential for viral infectivity. FeMV, however, defies this paradigm entirely. Groundbreaking work has demonstrated that the FeMV F protein contains a monobasic cleavage site (R-X-X-R↓) that is not recognized by furin but instead requires cleavage by cathepsin proteases, specifically cathepsin B and/or cathepsin L [7]. This cathepsin-dependent activation is a defining feature of the highly pathogenic zoonotic henipaviruses (Nipah virus and Hendra virus), which also belong to the Paramyxoviridae family but are classified in the distinct genus Henipavirus. The discovery that FeMV shares this unusual proteolytic activation strategy with henipaviruses positions it as a potential evolutionary "missing link" between the morbilliviruses and the henipaviruses, offering a unique window into the molecular transitions that may have accompanied the emergence of these divergent paramyxovirus lineages [7]. Structurally, the FeMV fusion protein exhibits a longer cytoplasmic tail compared to other morbilliviruses, a feature that may influence fusion efficiency, cell surface expression, or interactions with the matrix protein during assembly [7].

The biological consequences of cathepsin-dependent fusion are profound. Cathepsins are predominantly localized within endosomal and lysosomal compartments, requiring that FeMV virions be internalized by target cells via endocytosis before the F protein can be activated. This contrasts with furin-dependent morbilliviruses, which can undergo fusion directly at the plasma membrane following receptor engagement. The requirement for endosomal cathepsin cleavage likely influences the tissue tropism, pH sensitivity, and route of entry of FeMV, potentially explaining its predilection for renal epithelial cells, which are highly endocytically active, and its ability to establish persistent infections [7]. Furthermore, cathepsin dependence may contribute to the unique stability of FeMV at 4°C, where the virus retains high infectivity for at least 12 days, a characteristic that distinguishes it from the generally labile classical morbilliviruses [34].

Genetic Diversity, Recombination, and Genotypes

The genetic landscape of FeMV is characterized by remarkable diversity, with two major genotypes, FeMV genotype 1 (FeMV-1) and FeMV genotype 2 (FeMV-2 or FeMV-GT2), now recognized. These two genotypes share only approximately 78% nucleotide identity across the complete genome, a level of divergence that approaches or exceeds the species demarcation threshold for morbilliviruses [10, 18]. FeMV-1 is further subdivided into two distinct subclusters, designated FeMV-1A and FeMV-1B, which have been identified in multiple geographic regions including Asia, Europe, and the Americas [14, 16, 15]. The FeMV-1A clade encompasses the majority of characterized strains, including the prototype Hong Kong isolate, while FeMV-1B appears to be less prevalent but has been documented in Europe, particularly in Italy and Germany [16, 18]. FeMV-2, first isolated from cats with urinary tract disease, is more distantly related and exhibits distinct biological properties, including the ability to infect a broader range of primary cell types, including cells from the lung, brain, and peripheral blood [10].

The phylogeny of FeMV strains does not correlate strictly with geographic origin, suggesting that the virus has been circulating globally for a substantial period and that multiple introductions and cross-regional dissemination have occurred [5, 8]. However, a notable recombination event has been identified within the genome of the Japanese FeMV strain MiJP003. This strain is a likely recombinant between two distinct parental lineages, one from Japan and one from Hong Kong, with the recombination breakpoints located within the fusion (F) and hemagglutinin (H) genes [8]. This finding is of considerable significance because recombination is a potent driver of evolutionary change in RNA viruses, capable of generating novel antigenic variants, altering receptor binding properties, and facilitating host range expansion. The identification of recombination in FeMV highlights the dynamic nature of its evolution and raises the possibility that additional recombinant strains remain to be discovered, particularly in regions where multiple FeMV lineages co-circulate [35, 8].

The N gene sequences of FeMV isolates from Malaysia, when aligned with strains from Japan, Thailand, and other Asian countries, revealed 19 variable nucleotide sites, yet only two of these resulted in amino acid substitutions, underscoring the strong purifying selection acting on the nucleocapsid protein [35]. This conservation of the N protein contrasts with the hypervariability observed in the P gene and the antigenic diversity of the surface glycoproteins, suggesting that while the internal structural components of the virion are highly constrained, the external glycoproteins and accessory proteins are subject to ongoing immune-driven adaptation [14, 8].

Antigenic Uniqueness and Cross-Reactivity

Serological investigations have revealed that FeMV elicits exceptionally high titers of neutralizing antibodies in naturally infected cats, often far exceeding those observed during infections with other morbilliviruses in their respective hosts [13]. This robust humoral response is directed exclusively against FeMV-specific epitopes; sera from FeMV-infected cats with high neutralizing activity exhibit undetectable cross-neutralization against CDV, MeV, or other classical morbilliviruses. Conversely, antibodies raised against these other morbilliviruses show significant cross-neutralizing activity among themselves but fail to neutralize FeMV [13]. This antigenic uniqueness indicates that the surface glycoproteins (H and F) of FeMV are structurally and immunologically distinct from those of other morbilliviruses, a feature that likely reflects the divergent evolutionary history and potentially different receptor usage of FeMV.

Despite this lack of cross-neutralization, a clinically relevant cross-reactivity exists at the level of the nucleocapsid (N) protein. Antibodies directed against the N protein of FeMV have been demonstrated to cross-react with the N protein of CDV in both ELISA and Western blotting assays, and this phenomenon has been confirmed using feline plasma samples [1]. This cross-reactivity can lead to false-positive results in serological assays designed to detect anti-FeMV antibodies if CDV N protein is used as an antigen, or conversely, it may confound the interpretation of FeMV antigen detection in tissues where CDV infection is a differential diagnosis [1, 36]. The molecular basis for this cross-reactivity resides in conserved amino acid sequences within the N protein that are shared among morbilliviruses, as demonstrated by alignment studies showing identical residues at key positions across FeMV, CDV, and other members of the genus [35]. This finding has practical implications for both diagnostic assay development and epidemiological surveillance, emphasizing the need for careful validation of serological tools and the use of multiple antigen targets, such as the matrix (M) protein or the surface glycoproteins, to achieve adequate specificity [1, 13, 36].

Replication Dynamics and Cytopathology

At the cellular level, FeMV replication induces the formation of characteristic intracytoplasmic eosinophilic inclusion bodies in infected cells, which have been observed in renal tubular epithelial cells both in naturally infected cats and in experimentally infected cell cultures [31, 32, 17]. Ultrastructural examination of these inclusion bodies reveals the presence of electron-dense aggregations of viral ribonucleocapsid material exhibiting the typical herringbone-like morphology of paramyxovirus nucleocapsids [32, 17]. These inclusions represent sites of active viral replication and are often associated with cytopathic effects, including syncytium formation (cell-cell fusion) in susceptible cell lines, such as Crandell Rees feline kidney (CRFK) cells, and eventual cell death [29, 21]. The in vitro host range of FeMV is relatively restricted; among a panel of 32 cell lines derived from 13 species, only feline and African green monkey (Vero) cell lines were permissive for FeMV replication, with feline epithelial, fibroblastic, lymphoid, and glial cells all supporting infection [25]. Human cell lines were not susceptible, suggesting that the species barrier protecting humans from FeMV infection is robust, at least at the level of cellular entry [25].

Quantitative analyses of FeMV replication have demonstrated that the virus can establish persistent infections in cell culture and in vivo, with viral RNA detectable in urine for prolonged periods, often exceeding several months, even in the presence of high titers of neutralizing antibodies [10, 27, 30]. This capacity for persistence is a hallmark of FeMV infection and distinguishes it from the acute, self-limiting infections typical of most other morbilliviruses. The mechanistic basis for persistence is not fully understood but may relate to the cathepsin-dependent entry pathway, which could facilitate non-lytic release of viral particles, or to the immunomodulatory activities of the V and C accessory proteins, which may suppress antiviral interferon responses [7]. The viral polymerase complex (L protein) exhibits high processivity and fidelity, enabling robust replication in permissive cells, and assays targeting the L gene have been developed for sensitive molecular detection, with quantitative RT-PCR systems capable of detecting fewer than 10 copies of the viral genome [26, 37].

Molecular Pathogenesis and Renal Pathology

Molecular Determinants of Cellular Entry and Tropism

Feline morbillivirus (FeMV) occupies a unique and phylogenetically divergent position within the genus Morbillivirus, exhibiting molecular characteristics that distinguish it from classical morbilliviruses such as measles virus (MeV), canine distemper virus (CDV), and rinderpest virus. The molecular pathogenesis of FeMV is fundamentally anchored in its receptor usage, fusion machinery, and intracellular replication strategy, all of which shape its distinctive tissue tropism and pathological consequences, particularly within the feline kidney.

Unlike the classical morbilliviruses that utilize signaling lymphocytic activation molecule (SLAMF1/CD150) on immune cells and nectin-4 on epithelial cells as sequential entry receptors, FeMV has been confirmed to employ feline SLAMF1 as a functional cellular receptor [29, 13]. However, critical molecular differences exist. FeMV exhibits a restricted receptor usage profile compared to other morbilliviruses; while CDV and MeV can utilize SLAMF1 orthologs from multiple species, FeMV demonstrates stringent specificity for feline SLAMF1 [13]. This species-restricted receptor interaction likely constitutes a molecular barrier to cross-species transmission but simultaneously underpins the virus's ability to establish persistent infections within the feline host. Importantly, the receptor-binding domain of the FeMV hemagglutinin (H) protein is uniquely adapted to the feline SLAMF1 structure, as evidenced by the lack of cross-neutralizing activity between FeMV and other morbilliviruses despite the presence of high-titer neutralizing antibodies in infected cats [13]. This antigenic distinctiveness suggests that the H protein of FeMV has undergone significant evolutionary divergence, potentially driven by host-specific selective pressures within the feline immune environment.

The most striking molecular peculiarity of FeMV lies in its fusion glycoprotein (F) processing mechanism. Unlike all other known morbilliviruses, which rely on the ubiquitous cellular protease furin for cleavage of the fusion protein from its inactive precursor (F0) to the active fusogenic form (F1+F2), FeMV utilizes cathepsin-dependent proteolysis [7]. This finding is of profound pathogenic significance. Cathepsins are lysosomal cysteine proteases that require an acidic pH environment for optimal activity, and their involvement in FeMV F protein cleavage suggests that the virus may exploit endosomal compartments for membrane fusion, a strategy that bears mechanistic resemblance to the zoonotic henipaviruses rather than canonical morbilliviruses [7]. This cathepsin-dependent entry mechanism may influence the intracellular trafficking of viral particles, potentially directing FeMV to specific cellular compartments and contributing to its ability to establish persistent infections in renal epithelial cells. Furthermore, the pH-dependent nature of cathepsin-mediated fusion may confer differential tropism for tissues with specific microenvironments, such as the acidic milieu of the urinary tract.

The viral matrix (M) protein of FeMV also warrants molecular scrutiny. The M protein plays a central role in viral assembly and budding, and its interactions with the viral ribonucleocapsid (RNP) complex and host cellular membranes are critical for efficient particle production. Studies utilizing recombinant FeMV expressing fluorescent reporter proteins have demonstrated that the virus can replicate in primary renal epithelial cells, peripheral blood mononuclear cells (PBMCs), and even neural cells, indicating a broad cellular tropism that is facilitated by the functional orchestration of the M, F, and H proteins [10, 7]. The phosphoprotein (P) gene exhibits the highest degree of genetic polymorphism among FeMV strains [8], and positive selection sites are more frequently observed in this gene compared to other genomic regions [14]. The P gene product serves as a cofactor for the viral RNA-dependent RNA polymerase (L protein) and is also involved in counteracting host innate immune responses. The genetic plasticity of the P gene may allow FeMV to adapt to varying host immune pressures, facilitating persistent infection, a hallmark of FeMV biology.

Molecular Mechanisms of Renal Epitheliotropism and Viral Persistence

The kidney represents the primary target organ for FeMV, and the molecular basis for this renal epitheliotropism is multifaceted. Immunohistochemical (IHC) and in situ hybridization (ISH) studies have consistently localized FeMV antigens and viral RNA within the cytoplasm of renal tubular epithelial cells, particularly those lining the proximal and distal convoluted tubules, as well as the collecting ducts [31, 32, 33]. Ultrastructural analyses reveal electron-dense, herringbone-like ribonucleocapsid aggregations within the cytoplasm of infected tubular epithelial cells, corresponding to the eosinophilic intracytoplasmic inclusion bodies observed histologically [32, 17]. These inclusions represent sites of active viral replication and nucleocapsid assembly.

The molecular mechanisms underlying the establishment of persistent infection in the kidney are particularly intriguing. FeMV-infected cats can shed the virus in urine for extended periods, ranging from months to over 360 days, despite the presence of high titers of neutralizing antibodies in the serum [2, 10, 27]. This suggests that FeMV has evolved sophisticated immune evasion strategies that allow it to maintain replicative competence within renal epithelial cells despite systemic humoral immunity. One hypothesis implicates the virus's ability to replicate in a non-cytopathic manner within renal tubules, evading immune-mediated clearance by limiting the expression of viral antigens on the cell surface or by modulating the host interferon response. The nuclear localization of FeMV antigens and RNA in tubular epithelial cells, as demonstrated by both IHC and ISH [38], is particularly noteworthy. Unlike most paramyxoviruses, which replicate exclusively in the cytoplasm, the detection of FeMV signals within the nucleus suggests that the viral nucleoprotein (N) and/or other components of the RNP complex may translocate to the nucleus during replication. This nuclear phase could represent a strategy for immune evasion or may be related to the virus's ability to subvert host cell transcription machinery.

The matrix (M) protein has been shown to localize within inclusion bodies and is a reliable target for IHC detection of FeMV in renal tissues [32, 22]. The M protein not only orchestrates viral assembly but also interacts with host cellular proteins that regulate apoptosis and cell survival. The interplay between FeMV M protein and the host cell's apoptotic machinery may be central to the pathogenesis of renal injury. Furthermore, the viral nucleocapsid (N) protein exhibits antigenic cross-reactivity with that of CDV [1], a finding of significant diagnostic and evolutionary importance. This cross-reactivity indicates conserved structural epitopes within the N protein across morbilliviruses, but it also complicates serological interpretation and underscores the need for FeMV-specific diagnostic assays.

Apoptotic Pathways and Tubulointerstitial Injury

The molecular pathogenesis of FeMV-associated renal disease is increasingly linked to the induction of apoptotic cell death in renal tubular epithelial cells. A pivotal study by Zahro et al. (2025) provided quantitative evidence that FeMV infection is associated with a significant increase in caspase-3-mediated apoptosis within kidney tissues [31]. Cleaved caspase-3 (cCasp3) expression was significantly higher in FeMV-positive kidneys compared to FeMV-negative CKD controls (P = 0.005), and a strong positive correlation was observed between viral load (as determined by RT-dPCR) and cCasp3 expression (Spearman’s ρ = 0.8222, P = 0.007) [31]. This correlation suggests that the magnitude of viral replication directly influences the degree of apoptotic injury.

The mechanism by which FeMV triggers caspase-3 activation is still being elucidated. Classical morbilliviruses, including CDV and MeV, are known to induce apoptosis through both intrinsic (mitochondrial) and extrinsic (death receptor) pathways. In FeMV-infected kidneys, the expression of pro-apoptotic BAX and anti-apoptotic BCL-2 was not significantly different between FeMV-positive and negative groups, suggesting that the intrinsic mitochondrial pathway may not be the primary driver of apoptosis in this context [31]. This observation points toward the extrinsic pathway, triggered by death receptors such as Fas and TNF receptor 1, or possibly a direct activation of caspase-8 by viral proteins. The strong association between high viral load and elevated cCasp3 expression implies that active viral replication is a requisite for apoptotic induction. It is plausible that the accumulation of viral proteins, particularly the N protein or the fusion machinery, triggers endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), culminating in caspase-12 activation and subsequent caspase-3 cleavage.

The apoptotic loss of tubular epithelial cells has direct pathological consequences. The renal tubules are responsible for the reabsorption of water, electrolytes, and low molecular weight proteins. Apoptotic depletion of tubular epithelial cells leads to tubular atrophy, disruption of epithelial integrity, and impaired concentrating ability. Clinically, this manifests as isosthenuria or hyposthenuria, tubular proteinuria, and a progressive decline in glomerular filtration rate (GFR). In FeMV-infected cats, urinalysis frequently reveals a tubular pattern of proteinuria, characterized by a decrease in uromodulin (Tamm-Horsfall protein) and an increase in low molecular weight proteins on SDS-PAGE [39]. This pattern is directly attributable to tubular cell dysfunction and death, rather than glomerular damage.

Renal Histopathology: From Tubulointerstitial Nephritis to Fibrosis

The histopathological hallmark of FeMV-associated renal disease is lymphoplasmacytic tubulointerstitial nephritis (TIN), a pattern characterized by infiltration of lymphocytes and plasma cells into the interstitial space surrounding the renal tubules, accompanied by varying degrees of tubular degeneration, atrophy, and fibrosis [31, 2, 29, 33]. TIN is the most common histopathological correlate of feline chronic kidney disease (CKD), and its association with FeMV infection has been the subject of extensive investigation. However, it is essential to recognize that TIN is a non-specific response to renal injury, and not all FeMV-infected cats develop TIN, nor are all cases of TIN attributable to FeMV.

At the microscopic level, FeMV-positive kidneys exhibit patchy to diffuse interstitial infiltrates composed predominantly of CD3+ T lymphocytes and CD79a+ plasma cells, often forming lymphoid aggregates in severe cases [31, 22]. These infiltrates are associated with areas of tubular epithelial cell degeneration, necrosis, and apoptotic cell death, as confirmed by cCasp3 IHC. Eosinophilic intracytoplasmic inclusion bodies are observed in tubular epithelial cells, particularly at the corticomedullary junction and renal pelvis [31, 32]. These inclusions are pathognomonic for active FeMV replication and serve as a useful diagnostic feature at necropsy.

Fibrosis, as assessed by Masson’s trichrome staining, is significantly more pronounced in FeMV-positive kidneys compared to FeMV-negative controls (P = 0.040), and its severity correlates with viral load [31]. The fibrotic response is a consequence of chronic inflammation and repeated cycles of tubular injury and repair. Activated interstitial fibroblasts and myofibroblasts deposit extracellular matrix components, including collagen types I and III, leading to interstitial fibrosis and eventual glomerulosclerosis. The molecular drivers of fibrosis in FeMV infection likely include transforming growth factor-beta (TGF-β1), a master regulator of fibrogenesis that is upregulated in response to tubular cell injury and inflammation. The progression from acute TIN to end-stage fibrotic CKD is a dynamic process that may occur over months to years, and the rate of progression is likely influenced by host factors such as age, immune status, and co-infections.

However, the causal relationship between FeMV infection and TIN/CKD remains controversial. Several cross-sectional studies have failed to demonstrate a statistically significant association between FeMV PCR positivity and the presence of TIN or azotemic CKD [2, 40, 41]. For instance, studies in the UK and Italy found no significant difference in FeMV detection rates between cats with and without azotemic CKD [40, 42]. This inconsistency likely reflects the multifactorial nature of feline CKD, the high prevalence of FeMV in the general cat population (often exceeding 60% seroprevalence in some regions [19, 36]), and the chronic, slowly progressive nature of the disease. It is plausible that FeMV acts as an initiating or contributing factor in some cats, but that additional insults, such as hypertension, dietary factors, or concurrent infections (e.g., feline immunodeficiency virus, feline leukemia virus), are required for progression to clinical CKD [2, 27].

Experimental infection studies in specific-pathogen-free (SPF) cats have provided more definitive evidence for a pathogenic role of FeMV. Nikolin et al. (2022) demonstrated that experimental inoculation of SPF cats with FeMV resulted in the development of renal lesions, including TIN, without causing acute clinical disease [29]. Importantly, the lesions observed in experimentally infected cats mirrored those found in naturally infected animals, supporting a causative role for FeMV in renal pathology. These experimental studies also confirmed that FeMV is lymphotropic, as viral RNA was detected in PBMCs, CD4+ T cells, CD20+ B cells, and monocytes [10, 29]. The infection of immune cells, particularly during the acute phase of infection, may lead to lymphopenia and immune dysregulation, which could contribute to renal injury through both direct and indirect mechanisms.

The Spectrum of Renal Disease: From Acute Kidney Injury to Chronic Kidney Disease

The molecular pathogenesis of FeMV encompasses a spectrum of renal involvement, ranging from subclinical tubular proteinuria to acute kidney injury (AKI) and end-stage CKD. Clinical studies have documented that FeMV infection can be associated with different grades of renal dysfunction in cats that are younger than those typically affected by idiopathic CKD [39]. FeMV-positive cats often exhibit decreased urine specific gravity, reduced urine creatinine, and increased urine protein-to-creatinine ratio (UPC) compared to healthy controls [39]. These findings indicate subclinical kidney damage and impaired tubular concentrating ability, which may precede the development of azotemia by months or years.

Acute febrile illness associated with FeMV infection has been reported, characterized by fever, leukopenia, thrombocytopenia, and jaundice [28]. In these cases, viral RNA is detectable in blood and multiple systemic organs, including the kidneys. The detection of FeMV in the kidneys of cats with acute infection suggests that the virus can cause an acute tubulointerstitial nephritis that may, in some cases, progress to AKI. The degree of renal recovery following acute FeMV infection is unknown, but the potential for chronic sequelae is significant, particularly in cats that are unable to clear the virus.

The viral load in renal tissue is a critical determinant of pathological outcome. Zahro et al. (2025) demonstrated that higher FeMV RNA copy numbers in kidney tissue were significantly associated with increased cCasp3 expression and interstitial fibrosis [31]. This dose-response relationship supports a direct role for viral replication in driving renal injury. The renal tropism of FeMV is likely mediated by the expression of the feline SLAMF1 receptor on renal tubular epithelial cells, although the precise cellular distribution of SLAMF1 in the feline kidney warrants further investigation. Immunohistochemical studies have confirmed that FeMV antigen is predominantly localized in tubular epithelial cells, with minimal detection in glomerular structures [31, 33]. This tubular-centric distribution pattern explains the predilection for tubulointerstitial disease rather than glomerulonephritis.

In conclusion, the molecular pathogenesis of FeMV-associated renal pathology is a complex interplay between viral replication, receptor-mediated entry, cathepsin-dependent fusion, apoptosis induction, and host inflammatory responses. The virus's ability to establish persistent infection in renal tubular epithelial cells, evade immune clearance, and trigger caspase-3-mediated apoptosis are central to the development of TIN and fibrosis. While the causal link between FeMV infection and CKD has not been definitively established for all cases, the accumulating experimental and histopathological evidence strongly implicates FeMV as a significant contributor to feline renal disease. The genetic diversity among FeMV strains, including the presence of two major genotypes (FeMV-1 and FeMV-2) [10, 18], may influence pathogenic potential, and future studies should focus on correlating specific viral genotypes with clinical and pathological outcomes.

Host Immune Response and Antigenic Cross-Reactivity

The host immune response to feline morbillivirus (FeMV) is a complex and evolving area of investigation, distinguished by several features that set it apart from classical morbillivirus infections. Unlike measles virus (MeV) or canine distemper virus (CDV), which typically induce robust, life-long protective immunity following acute, self-limiting infections, FeMV appears to establish a unique host–pathogen relationship characterized by persistent viral shedding in the face of a strong humoral response. This paradox, combined with the emerging evidence of antigenic cross-reactivity between FeMV and CDV, presents significant challenges for both serological diagnostics and our mechanistic understanding of FeMV pathogenesis.

Humoral Immune Response: Neutralizing Antibodies and Seroprevalence

FeMV-infected cats mount a pronounced and sustained antibody response directed primarily against structural proteins, including the nucleocapsid (N), matrix (M), and surface glycoproteins (hemagglutinin [H] and fusion [F]). The development of recombinant-protein-based indirect enzyme-linked immunosorbent assays (i-ELISAs) targeting the matrix protein has enabled large-scale serosurveillance [36]. In a study of 136 cats in Thailand, 68.4% were seropositive by i-ELISA, with a sensitivity of 90.1% and specificity of 75.6% compared to Western blotting [36]. Such high seroprevalence rates, mirrored in free-roaming cats in Chile (63% against FeMV-1 and/or FeMV-2) [19] and in Japanese populations (29% combined RNA and/or antibody positivity) [43], underscore the widespread exposure to FeMV across global cat populations.

A particularly striking aspect of the humoral response is the magnitude of neutralizing antibody titers. Using a plaque assay system in Vero cells stably expressing feline SLAMF1, Tashiro et al. demonstrated that sera from naturally FeMV-infected domestic cats contained exceptionally high titers of FeMV-specific neutralizing antibodies, often far exceeding those observed in animals infected with other morbilliviruses [13]. These high titers are paradoxical given that infected cats frequently shed virus in urine for months or even years [10, 30]. This phenomenon suggests that neutralizing antibodies, while present, may be ineffective at clearing the infection from renal tubular epithelial cells, the primary site of viral persistence. The inability of systemic humoral immunity to eradicate an established, cell-associated infection is reminiscent of the immune evasion strategies employed by other persistent RNA viruses and implies that local immune factors within the kidney microenvironment may be crucial.

Importantly, the neutralizing antibody response is exquisitely specific to FeMV. Sera with high neutralizing activity against FeMV exhibited undetectable cross-neutralizing activity against MeV, CDV, or other classical morbilliviruses [13]. This antigenic distinctiveness resides in the surface glycoproteins; the receptor-binding domain of FeMV’s hemagglutinin appears uniquely adapted to feline SLAMF1 and fails to engage SLAMF1 orthologs from other species or to be neutralized by heterologous antisera [13, 6]. This lack of cross-neutralization is a critical finding, as it implies that prior exposure to CDV, common in regions where dogs and cats coexist, is unlikely to confer protective immunity against FeMV. Conversely, it also means that FeMV serological assays are not confounded by antibodies to other morbilliviruses, except in the specific case of the N protein (discussed below).

Cell-Mediated Immunity and Pathogenesis

While humoral responses dominate the serological literature, cell-mediated immunity (CMI) is increasingly recognized as a driver of both viral control and immunopathology. FeMV exhibits tropism for immune cells, including CD4+ T cells, CD20+ B cells, and monocytes in peripheral blood mononuclear cells (PBMCs) [10]. Infection of these populations may impair adaptive immune function, contributing to the persistent infection phenotype. Immunohistochemical studies have localized FeMV antigens within infiltrating lymphocytes in renal parenchyma and in lymphoid cells of the spleen, suggesting that the virus actively replicates in immune compartments [22]. This lymphotropism, combined with the utilization of SLAMF1 (CD150) as a cellular receptor, a molecule expressed on activated T and B cells, dendritic cells, and macrophages, places FeMV squarely within the classical morbillivirus receptor paradigm, yet with distinct biological outcomes [29, 7].

The renal pathology associated with FeMV infection is intimately linked to the local immune response. In naturally infected cats, the hallmark histopathological finding is lymphoplasmacytic tubulointerstitial nephritis (TIN), characterized by infiltration of lymphocytes and plasma cells into the renal interstitium [31, 33, 22]. This inflammatory infiltrate is not merely a bystander effect; it is an active immunological response to viral replication within tubular epithelial cells. Zahro et al. demonstrated that FeMV antigen and RNA are localized in renal tubular epithelial cells, and that viral load is strongly correlated with cleaved caspase-3 (cCasp3) expression, a marker of apoptosis [31, 38]. The Spearman correlation coefficient (ρ = 0.8222, P = 0.007) between viral load and cCasp3 expression indicates a tight link between viral replication and caspase-dependent apoptotic activity [31]. This suggests that cytotoxic T lymphocytes (CTLs) or natural killer (NK) cells may eliminate infected tubular cells via perforin/granzyme or Fas-mediated pathways, triggering apoptosis and subsequent fibrosis.

However, the relationship between CMI and renal damage is not straightforward. FeMV-positive kidneys also show increased interstitial fibrosis compared to FeMV-negative CKD controls [31]. Yet, markers of B-cell activity (BCL-2) and pro-apoptotic signaling (BAX) were not significantly elevated, indicating that the apoptotic pathway is selectively activated [31]. The absence of consistent associations with TIN severity raises the possibility that individual host genetic factors, coinfections (e.g., feline leukemia virus, feline immunodeficiency virus), or the specific FeMV genotype may modulate the immunopathological outcome [2, 27, 3].

Antigenic Cross-Reactivity with Canine Distemper Virus

A critical dimension of the FeMV-host immune interface is the phenomenon of antigenic cross-reactivity between FeMV and CDV, specifically at the level of the nucleocapsid (N) protein. This issue has profound implications for the interpretation of serological and immunohistochemical assays, as well as for our understanding of morbillivirus evolution and host range.

Khin et al. provided definitive evidence for this cross-reactivity using recombinant N proteins from both FeMV and CDV in ELISAs and Western blots [1]. Among 100 cat plasma samples from Japan, 20 were positive for anti-FeMV N antibodies, and 6 of these also reacted with the CDV N protein. All six cross-reactive samples were double-positive for anti-FeMV antibodies, but critically, none contained CDV genomic RNA when tested by RT-qPCR (detection limit 100 copies) [1]. This rules out concurrent CDV infection as the cause of the reactivity and confirms that the antibodies raised against FeMV N protein are capable of binding the homologous CDV N epitope. Western blotting with purified proteins further validated the specificity of these antibodies to their target antigens, eliminating the possibility of non-specific binding [1].

The molecular basis for this cross-reactivity lies in the conservation of N protein sequences among morbilliviruses. Alignment of the N gene reveals similar amino acid sequences in conserved regions across FeMV, CDV, and other morbilliviruses [35]. The N protein is the most abundant viral protein and is highly immunogenic, making it a common target for diagnostic ELISAs and immunohistochemistry. Consequently, in regions where CDV is enzootic in canine populations and cats are exposed (either through vaccination or natural infection), the potential for false-positive FeMV serology is substantial. This is not merely a theoretical concern; the 6% cross-reactivity rate observed in the Japanese study [1] could lead to significant overestimation of FeMV seroprevalence in field studies that rely solely on N-protein-based assays.

The practical implications for diagnostic accuracy are twofold. First, for serosurveillance, assays based on the N protein must be interpreted with caution, especially in populations with high CDV exposure. Second, for immunohistochemical detection of FeMV antigen in tissues, antibodies targeting the N protein may yield false-positive signals if the tissue contains CDV antigen (e.g., from a concurrent, unrecognized CDV infection). The rub is that the M protein-based i-ELISA developed by Chaiyasak et al. [36] exhibited a substantial false-positive rate of 11.8% even when validated against Western blotting, indicating that cross-reactivity is not limited to the N protein alone. Future assay development should prioritize the use of glycoprotein (H or F) antigens, which are more antigenically distinct and less conserved across the genus [13].

From an evolutionary perspective, the N-protein cross-reactivity between FeMV and CDV is a vestige of their common ancestry. FeMV is the most divergent member of the Morbillivirus genus, and its N protein retains epitopes shared with CDV that have been lost in more distantly related paramyxoviruses [6, 11]. This immunological footprint provides a window into the evolutionary history of morbilliviruses, suggesting that the ancestors of FeMV and CDV shared a common host or geographic range at some point in the past.

Implications for Diagnostics, Epidemiology, and Vaccine Development

The interplay between the host immune response and antigenic cross-reactivity directly impacts the design and interpretation of FeMV studies. The high seroprevalence reported globally, ranging from 14.5% in Italy to 68.4% in Thailand [27, 36], must be re-evaluated in light of potential cross-reactivity with CDV. Moreover, the finding that naturally infected cats can simultaneously harbor high neutralizing antibody titers and shed virus persistently [10, 13] indicates that antibody-mediated neutralization is not a reliable correlate of protection for FeMV, unlike MeV or CDV. Vaccine development efforts, should they be undertaken, will need to target T-cell epitopes or generate mucosal immunity in the urinary tract to prevent renal persistence.

The WOAH (World Organisation for Animal Health) has not yet established standardized diagnostic guidelines for FeMV, largely due to the absence of validated, cross-reactivity-free serological assays. As the global cat population faces an increasing burden of chronic kidney disease, the leading cause of morbidity and mortality in domestic cats [4, 44], the need for accurate FeMV diagnostics becomes urgent. The integration of RT-qPCR with serology, as advocated by several groups [43, 36], offers a more comprehensive approach but is not feasible in resource-limited settings. Until multiplex assays that distinguish FeMV, CDV, and other paramyxoviruses are developed, the scientific community must remain vigilant against the confounding effects of antigenic cross-reactivity.

Epidemiology and Global Distribution

The emergence of feline morbillivirus (FeMV) as a globally distributed pathogen represents a paradigm shift in our understanding of morbillivirus ecology and the potential infectious origins of one of the most pervasive diseases in domestic cats. Since its initial identification in 2012 from stray cats in Hong Kong [2, 3, 4], FeMV has been documented across an astonishingly broad geographic and host range, fundamentally challenging the assumption that morbilliviruses are restricted to narrow, species-specific transmission cycles. The epidemiology of FeMV is characterized by high genetic diversity, variable prevalence rates that are heavily influenced by diagnostic methodology, and accumulating evidence of multi-host tropism that raises critical questions regarding viral maintenance, spillover dynamics, and the true burden of FeMV-associated disease in feline populations worldwide.

Global Prevalence and Geographic Distribution

FeMV has been detected on at least five continents, with molecular or serological evidence reported across Asia, Europe, North America, South America, Africa, and Oceania [4, 26]. The virus is now considered endemic in many regions, though prevalence estimates vary dramatically depending on the population studied, the sample type analyzed, and the detection method employed. In Asia, where FeMV was first discovered, prevalence rates have been among the highest reported. In Japan, epidemiological surveys have demonstrated that 15.1% of urine samples from veterinary clinic populations test positive by real-time RT-PCR [37], while broader sampling including both blood and urine has yielded detection rates of approximately 29% when combining serological and molecular methods [43]. A separate Japanese study focusing on cats presenting with acute febrile illness found an even more striking 31.4% positivity rate in blood samples, suggesting that acute infection may be substantially more common than previously appreciated [28]. In Thailand, molecular screening of household and shelter cats has identified an overall FeMV RNA prevalence of 11.9% [14], while serological surveys using a recombinant matrix protein ELISA have revealed exposure rates as high as 68.4% [36], indicating that the vast majority of infections may be subclinical or cleared before molecular detection is possible. Malaysian studies have similarly confirmed FeMV circulation, with molecular detection rates of 15.5% to 35.2% depending on the sensitivity of the PCR assay employed [35, 26, 45], and phylogenetic analysis has demonstrated that Malaysian isolates cluster closely with strains from Japan and Thailand, suggesting regional viral circulation and potential cross-border transmission [35].

European epidemiology has been particularly well-characterized, with studies from Italy, Germany, Switzerland, and the United Kingdom all confirming endemic FeMV circulation. In Italy, a comprehensive investigation of cats from the southern regions found FeMV RNA in 2.4% of blood samples but 16.1% of urine samples, underscoring the importance of sample selection in prevalence estimation [27]. A separate Italian study of feline colonies versus household cats revealed that colony cats had substantially higher infection rates, consistent with increased transmission in dense populations [41]. In northwestern Italy, molecular screening detected FeMV in 7.3% of urine samples and 8% of kidney samples, with phylogenetic analysis revealing the first identification of genotype 1-B in this region [16]. German investigators have successfully isolated FeMV and generated complete genome sequences, confirming that European strains share approximately 78% nucleotide homology with Asian isolates and supporting the division of FeMV into at least two distinct genotypes [10, 18]. In the United Kingdom, the first detection of FeMV in geriatric cats was reported in 2018, with sequencing identifying five distinct morbillivirus strains, though no statistically significant association was found between FeMV detection and azotemic chronic kidney disease (CKD) in this population [40].

The Americas have also demonstrated widespread FeMV circulation. In the United States, initial detection occurred in 2016 from urine samples of domestic cats, with subsequent characterization revealing persistent viral shedding patterns and genetic diversity consistent with endemic circulation [30]. Brazilian studies have been particularly illuminating, with a large survey of 276 cats from Western Brazil finding a remarkable 34.7% paramyxovirus-positive rate, though this included both FeMV and feline paramyxovirus (FPaV) [15]. Importantly, no statistical association was identified between viral RNA shedding and kidney disease in this Brazilian population, highlighting the complexity of FeMV pathogenesis. Chilean serological surveys have further expanded our understanding, with 63% of free-roaming domestic cats showing antibodies against one or both FeMV genotypes, and a significant sex-based difference observed, antibodies directed exclusively against genotype 2 were significantly more prevalent in male cats, potentially offering clues about transmission routes [19].

Host Range Expansion: Beyond the Domestic Cat

Perhaps the most epidemiologically significant finding in recent FeMV research is the demonstration of infection in non-felid hosts. This fundamentally alters our understanding of FeMV as a pathogen strictly adapted to domestic cats and raises the possibility of wildlife reservoirs capable of sustaining viral transmission independent of domestic cat populations. The first evidence of FeMV infection in a non-felid host came from dogs with respiratory disease in Thailand, where FeMV-1 was detected in 12.39% of dogs presenting with respiratory illness, with viral antigen confirmed by immunohistochemistry in lung, kidney, lymphoid, and brain tissues of necropsied animals [20]. This finding was not merely incidental; viral isolation from both deceased and living dogs with respiratory disease confirmed active infection and replication, expanding the known tropism of FeMV to include canids.

Even more striking was the detection of FeMV in white-eared opossums (Didelphis albiventris) in Brazil [21]. This synanthropic marsupial, inhabiting peri-urban areas of southern Brazil, was found to harbor FeMV RNA in lung and kidney tissues, with histopathological evidence of interstitial pneumonia and lymphocytic nephritis. Immunohistochemistry confirmed intralesional viral antigen, and the opossum strain was successfully isolated in Crandell Rees feline kidney cells, producing syncytia formation and cell death characteristic of morbillivirus infection [21]. This discovery raises the alarming possibility that FeMV may circulate in wildlife populations with minimal clinical disease, serving as a reservoir for periodic spillover into domestic cats and potentially other species.

Wild felids are also susceptible. In Thailand, FeMV-1 was identified in two black leopards (Panthera pardus) with severe azotemia and tubulointerstitial nephritis, with molecular and immunohistochemical evidence confirming renal tubular epithelial cell infection and lymphoid cell tropism [22]. In Chile, screening of guignas (Leopardus guigna), a wild felid species, detected paramyxovirus RNA in 31% of kidney samples, with phylogenetic analysis revealing two well-supported clusters related to isolates from domestic cats, rodents, and bats [23]. Notably, no significant histopathological changes were recorded in infected guignas, suggesting that these wild felids may serve as asymptomatic carriers. This pattern of infection without disease in wildlife hosts mirrors the ecology of other morbilliviruses and suggests that FeMV may be more widely distributed in nature than currently recognized.

Genetic Diversity and Viral Evolution

The genetic architecture of FeMV is characterized by substantial heterogeneity that has driven the classification of at least two major genotypes, designated FeMV-1 and FeMV-2, with FeMV-1 further subdivided into clades 1A and 1B [2, 10, 16, 18]. Whole genome sequencing of FeMV-2 isolates has demonstrated approximately 78% nucleotide homology to FeMV-1 strains, confirming that these represent distinct genetic lineages with potentially different biological properties [10]. This genetic diversity is not merely taxonomic; it may have clinical and epidemiological implications. FeMV-2 isolates have been shown to infect primary cells from lung, kidney, brain, and peripheral blood, including CD4+ T cells, CD20+ B cells, and monocytes, and infected cats shed virus continuously for several months despite the presence of neutralizing antibodies [10]. The existence of such prolonged shedding in the face of humoral immunity suggests that FeMV has evolved mechanisms for immune evasion that may facilitate persistence in populations.

Recombination has been identified as a significant evolutionary force in FeMV. The Japanese strain MiJP003 has been characterized as a probable recombinant between two distinct viral lineages circulating in Japan and Hong Kong, with the recombination event occurring within the F and H genes [8]. This observation is critical because recombination in morbilliviruses can generate novel antigenic variants capable of escaping pre-existing immunity, potentially driving epidemic waves in populations with prior exposure. The selective pressure analysis of FeMV-1 genomes has further revealed that while the virus is predominantly under negative (purifying) selection, positive selection sites are more frequently observed in the phosphoprotein gene, which may reflect ongoing adaptation to host immune pressure [14].

Phylogenetic analyses have consistently failed to demonstrate clear geographic clustering of FeMV strains. Isolates from Japan, Thailand, Malaysia, Italy, Germany, and the United States intermingle on phylogenetic trees, suggesting that viral dispersal has occurred rapidly and repeatedly across continents [35, 18, 8]. This pattern is consistent with international movement of infected cats, whether through pet travel, relocation, or potentially through undocumented transport of animals. The lack of phylogeographic structure also implies that FeMV may have been circulating in global cat populations for considerably longer than the decade since its formal discovery, with the 2012 Hong Kong identification representing the first recognition rather than the first emergence.

Temporal Shedding Patterns and Transmission Dynamics

Longitudinal studies have fundamentally reshaped our understanding of FeMV epidemiology by revealing that viral shedding in urine can persist for extended periods, potentially for the lifetime of the infected cat. Follow-up investigations in Italy have documented urine shedding lasting up to 360 days [27], while experimental infections have confirmed persistent viral excretion despite the presence of neutralizing antibodies [10, 29]. This pattern of chronic shedding in urine positions FeMV uniquely among morbilliviruses, which typically cause acute, self-limiting infections characterized by high-level shedding during a brief period followed by clearance or, in the case of canine distemper virus and measles, occasional persistent infection of the central nervous system. The urinary shedding pattern has immediate implications for transmission: cats may serve as long-term reservoirs, contaminating shared litter boxes, environmental surfaces, and potentially water sources.

The primary route of FeMV transmission remains poorly defined, but mounting evidence supports direct contact and fecal-oral or urinary-oral routes. The detection of higher viral loads in urine compared to other tissues [2, 29], coupled with the epitheliotropic nature of FeMV in renal tubular epithelial cells [32, 33], strongly suggests that urine is the primary vehicle for horizontal transmission. However, the detection of FeMV RNA in blood during acute infection [28, 27] and the demonstration of viral lymphotropism [29] indicate that viremia may facilitate systemic dissemination and potential transmission via other routes, including possibly respiratory secretions. The serological finding that antibodies against FeMV-2 are significantly more prevalent in male cats in Chile [19] raises the intriguing possibility of sex-based differences in behavior (e.g., urine marking, fighting) that could influence transmission dynamics.

Seroprevalence and the Challenge of Cross-Reactivity

Serological studies have consistently revealed exposure rates far exceeding molecular detection rates, indicating that many cats clear infection or maintain low-level persistent infections that fall below the detection threshold of RT-PCR. In Thailand, an indirect ELISA using recombinant matrix protein demonstrated 68.4% seropositivity despite only 8.1% RT-PCR positivity [36]. These data suggest that the vast majority of cats encountered FeMV at some point in their lives, and that molecular surveys substantially underestimate the true prevalence of infection. However, the interpretation of serological data must be approached with caution due to documented antigenic cross-reactivity between FeMV and canine distemper virus (CDV) nucleocapsid proteins. A critical study using affinity-purified recombinant N proteins demonstrated that 6 out of 100 cat plasma samples positive for anti-FeMV antibodies also showed reactivity against CDV N protein, and all six CDV-reactive samples were double-positive for anti-FeMV antibodies [1]. Importantly, RT-qPCR failed to detect CDV genomic RNA in these samples, confirming that the cross-reactivity was due to antibody recognition of shared epitopes rather than active CDV infection. This finding has profound implications for serosurveillance: studies using N-protein-based ELISAs without confirmatory testing may overestimate FeMV-specific seroprevalence, and the true extent of CDV exposure in cat populations remains unknown.

Conversely, FeMV neutralizing antibodies appear to be exquisitely specific. A plaque assay using Vero cells expressing feline SLAMF1 demonstrated that sera from FeMV-infected cats contain exceptionally high titers of neutralizing antibodies, yet exhibit undetectable cross-neutralization against other morbilliviruses [13]. This immunological uniqueness indicates that while structural proteins share some epitopes, the surface glycoproteins responsible for neutralization are antigenically distinct, which has implications for vaccine development and serological diagnosis.

Risk Factors and Demographic Associations

Several studies have identified demographic and environmental risk factors for FeMV infection. Age appears to be a significant determinant, with older cats more frequently infected [27]. The association with age may reflect cumulative exposure risk, longer duration of potential shedding in persistently infected animals, or age-related immunological changes that increase susceptibility to reactivation or re-infection. Housing conditions also influence risk: cats from rescue catteries and multi-cat households have higher infection rates compared to household cats [27, 41], consistent with increased transmission opportunities in dense populations. Foundling cats (those found as strays) are more likely to be infected, possibly reflecting prior exposure in unsanitary environments or prior co-infections that compromise immune function [27].

Co-infections with retroviruses, particularly feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV), have been significantly associated with FeMV positivity [27]. This association may be bidirectional: retroviral immunosuppression may facilitate FeMV acquisition or reactivation, while FeMV-induced lymphopenia [2] may accelerate retroviral disease progression. The clinical significance of these interactions warrants further investigation, as they may contribute to the variability in FeMV-associated pathology observed across populations.

Implications for Global Surveillance and Public Health Policy

The global distribution of FeMV, its ability to infect multiple mammalian species, and its potential association with CKD, a leading cause of morbidity and mortality in domestic cats, collectively argue for enhanced surveillance at the international level. The World Organisation for Animal Health (WOAH) does not currently list FeMV as a notifiable disease, but the virus meets many criteria warranting attention: it is an emerging pathogen with a wide geographic distribution, it causes chronic disease with significant welfare implications, and it has demonstrated capacity for cross-species transmission. The detection of FeMV in synanthropic wildlife [21] raises the possibility that the virus could establish sylvatic cycles independent of domestic cats, potentially complicating control efforts and increasing the risk of spillover to naive populations.

Standardized diagnostic protocols are urgently needed to enable meaningful comparison of prevalence data across regions. The availability of validated real-time RT-PCR assays targeting conserved regions of the FeMV genome [26, 37, 46] provides a foundation for molecular surveillance, but the development of confirmatory serological assays that account for cross-reactivity with CDV remains a priority. Until such tools are widely deployed, the true global burden of FeMV infection will remain incompletely characterized, and our ability to track viral emergence, spread, and evolution will be constrained.

Diagnostic Methods and Challenges

The accurate diagnosis of feline morbillivirus (FeMV) infection is fraught with complexities that stem from the virus's unique biological characteristics, its extensive genetic diversity, and the inherent limitations of current detection platforms. Unlike classical morbilliviruses such as canine distemper virus (CDV) or measles virus, FeMV presents a diagnostic conundrum that requires a multi-modal approach, integrating molecular, serological, and histopathological techniques. No single assay has emerged as a definitive gold standard, and the interpretation of results must be contextualized within the clinical presentation, sampling strategy, and the specific viral genotype in question. This section provides an exhaustive analysis of the diagnostic armamentarium available for FeMV, critically evaluating the biological underpinnings, performance characteristics, and persistent challenges that define each method.

Molecular Detection: Nucleic Acid Amplification Techniques

The detection of FeMV RNA remains the most direct and widely employed method for confirming active infection, particularly given the virus's propensity for urinary shedding. Reverse transcription quantitative PCR (RT-qPCR) assays have been developed targeting several genomic regions, including the L gene [37, 46], the N gene [26], and the P/V/C gene [46]. These assays offer high analytical sensitivity, with detection limits reported as low as 10 copies of template DNA for L-gene assays [37] and 1.74 × 10⁴ copies/μL for N-gene assays [26]. The TaqMan-based real-time RT-PCR targeting the N gene has demonstrated superior sensitivity compared to conventional RT-PCR, detecting 35.2% of clinical samples as positive versus only 15.5% by conventional methods [26]. However, the quantitative nature of these assays is critical, as viral loads in clinical specimens are typically low [46], and the relationship between viral load and pathological outcome is nuanced. Source [31] demonstrated a strong positive correlation between viral load and cleaved caspase-3 expression in renal tissues (ρ = 0.8222, P = 0.007), suggesting that higher viral burdens may drive apoptotic activity, yet no such correlation was observed with tubulointerstitial nephritis (TIN) or fibrosis scores [31]. This indicates that molecular detection alone cannot predict renal pathology.

A significant challenge for molecular diagnostics is the extensive genetic heterogeneity of FeMV. The virus is classified into at least two major genotypes, FeMV-1 and FeMV-2, with FeMV-1 further subdivided into clades 1A and 1B [10, 16, 18]. Nucleotide identity between genotypes can be as low as 78% [10], and recombination events, particularly within the F and H genes, have been documented [8]. This genetic plasticity necessitates careful primer and probe design to ensure broad reactivity. The development of a pan-morbillivirus RT-PCR targeting the L gene was an early attempt to address this, but it lacks the specificity to differentiate FeMV from other paramyxoviruses [46]. More targeted assays, such as those based on the N gene, must be continuously validated against circulating strains. Source [26] reported no cross-reactivity with CDV, Newcastle disease virus, measles virus, feline coronavirus, or feline leukemia virus, but this does not guarantee performance against all FeMV variants. The use of reverse transcription digital PCR (RT-dPCR) has emerged as a tool for absolute quantification without the need for standard curves, offering improved precision for low-copy-number targets [31]. However, this technology is not yet widely available in diagnostic laboratories.

Beyond PCR, alternative nucleic acid amplification methods have been explored. Reverse transcription loop-mediated isothermal amplification (RT-LAMP) offers a rapid, simple, and highly specific alternative for field-deployable diagnostics, with a detection limit of 0.12 TCID₅₀ per reaction [47]. While promising for resource-limited settings, RT-LAMP is less amenable to multiplexing and quantification compared to RT-qPCR. Unbiased next-generation sequencing (NGS) has proven invaluable for the discovery of novel FeMV strains and for characterizing the full viral genome directly from clinical samples [28, 48, 49]. Source [48] utilized high-throughput sequencing to detect FeMV in archived brain tissue from a cat with encephalitis, obtaining a full-length genome. This metagenomic approach is critical for identifying divergent strains that may escape PCR-based detection, but its cost, complexity, and turnaround time preclude routine diagnostic use.

Serological Assays: Antibody Detection and Its Pitfalls

Serological testing for anti-FeMV antibodies is essential for understanding population exposure, monitoring seroconversion, and investigating the kinetics of the humoral immune response. However, the interpretation of serological data is profoundly complicated by antigenic cross-reactivity, particularly between FeMV and CDV. Source [1] demonstrated that antibodies against the nucleocapsid (N) protein of FeMV in cat plasma samples cross-react with the N protein of CDV. In a study of 100 cat plasma samples, 20 were positive for anti-FeMV antibodies, and 6 of these were also positive for anti-CDV antibodies. All 6 double-positive samples were negative for CDV genomic RNA by RT-qPCR, confirming that the reactivity was due to cross-reactivity rather than dual infection [1]. This finding has profound implications for the specificity of any serological assay that employs N protein as the antigen, including enzyme-linked immunosorbent assays (ELISAs) and Western blotting. The risk of false-positive results is substantial, particularly in regions where CDV is endemic in wildlife or unvaccinated dog populations.

Several ELISA formats have been developed to mitigate this issue. An indirect ELISA targeting the recombinant matrix protein (rFeMV-M) of FeMV was evaluated in 136 cats, demonstrating a sensitivity of 90.1% and a specificity of 75.6% compared to Western blotting [36]. The positive predictive value was 88.2%, and the negative predictive value was 79.1%, with substantial agreement between the ELISA and Western blot (κ = 0.664) [36]. However, the specificity of 75.6% indicates a significant false-positive rate (11.8% of seropositive cats were false positives), which could lead to misdiagnosis [36]. The matrix protein may be less conserved than the N protein across morbilliviruses, potentially reducing cross-reactivity, but this has not been systematically evaluated. An alternative approach using an indirect immunofluorescence assay (IFA) with FeMV-N protein-expressing HeLa cells has been employed in epidemiological studies [43, 23, 19]. Source [43] reported that 21% of cats in Japan had antibodies against FeMV-N protein by IFA, and the assay allowed classification of infected cats into different phases: RNA+/Ab+ (persistent infection), RNA+/Ab- (early infection), and RNA-/Ab+ (resolved infection). The IFA offers the advantage of visualizing antibody binding to native viral proteins, but it is subjective, labor-intensive, and difficult to standardize.

The most definitive serological tool is the virus neutralization test (VNT), which measures functional antibodies capable of blocking viral entry. Source [13] established a plaque assay system using Vero cells stably expressing feline SLAMF1 (CD150) and demonstrated that FeMV-infected cats produce exceptionally high titers of neutralizing antibodies, often far exceeding those seen with other morbilliviruses. Critically, these antibodies showed no cross-neutralizing activity against CDV, measles virus, or other morbilliviruses, confirming the antigenic uniqueness of FeMV surface glycoproteins [13]. This finding suggests that VNT-based assays are highly specific and should be considered the gold standard for serological diagnosis. However, the VNT requires live virus, cell culture facilities, and biosafety containment, limiting its use to specialized research laboratories. The development of pseudotype-based neutralization assays could overcome these barriers, but such tools are not yet commercially available.

Antigen Detection and In Situ Localization

Immunohistochemistry (IHC) and in situ hybridization (ISH) are indispensable for localizing FeMV antigens and RNA within tissues, providing direct evidence of viral tropism and its association with histopathological lesions. Polyclonal antibodies against the FeMV matrix (M) protein have been widely used for IHC, labeling viral antigens in renal tubular epithelial cells, bronchiolar epithelium, lymphocytes, macrophages, and neuroglial cells [32, 22, 17]. Source [32] demonstrated that FeMV-M antigen was present in eosinophilic intracytoplasmic inclusion bodies within renal tubular epithelial cells, and ultrastructural analysis confirmed the presence of herringbone-like ribonucleocapsid aggregates at these sites. Double IHC revealed FeMV antigen in astroglia and oligodendroglia but not microglia, suggesting a specific neurotropism [32]. ISH targeting FeMV RNA has been employed to detect viral nucleic acids in brain sections with inflammatory lesions, confirming the association between FeMV and encephalitis [48]. In renal tissues, ISH signals were observed in both the nucleus and cytoplasm of tubular epithelial cells, suggesting that FeMV replication may involve nuclear stages, a feature unusual for paramyxoviruses [38].

The sensitivity of IHC and ISH is highly dependent on antibody quality, tissue fixation, and antigen retrieval methods. Source [31] reported that IHC detected FeMV antigens in 7 of 9 PCR-positive kidney cases, while ISH detected signal in all 9 cases, indicating that ISH may be more sensitive for detecting low-level viral RNA. The use of antibodies against different viral proteins (e.g., N protein vs. M protein) may yield different results, as N protein is typically more abundant during infection. Source [33] used IHC and immunofluorescence to detect FeMV antigens and found that tissue injury scores were significantly higher in antigen-positive kidneys, particularly for tubular atrophy, interstitial fibrosis, and glomerulosclerosis. However, the absence of consistent associations between FeMV antigen detection and TIN in some studies [16, 41] highlights the need for standardized scoring systems and larger sample sizes.

Major Diagnostic Challenges and Unresolved Issues

The diagnostic landscape for FeMV is dominated by several interconnected challenges that hinder both clinical diagnosis and research progress.

1. Antigenic Cross-Reactivity and Serological Specificity: As detailed above, the cross-reactivity between anti-FeMV N protein antibodies and CDV N protein is a critical impediment [1]. This is not merely a theoretical concern; in the study by Khin et al. (2025), 30% of anti-FeMV-positive samples were also reactive against CDV [1]. Given that CDV is a common pathogen in dogs and can infect felids [24], and that many cats may have been exposed to CDV through contact with dogs or wildlife, the potential for misclassification is high. The use of matrix protein-based ELISAs may reduce this risk, but the specificity of 75.6% reported by Chaiyasak et al. (2024) [36] is still suboptimal for a diagnostic test. The development of assays targeting the hemagglutinin (H) protein, which is the primary target of neutralizing antibodies and is antigenically distinct from CDV [13], may offer a solution. However, the H protein is more variable than the N or M proteins, and recombinant H protein production is technically challenging.

2. Genetic Diversity and Assay Coverage: The existence of two major FeMV genotypes (FeMV-1 and FeMV-2) with only 78% nucleotide identity [10], along with multiple subtypes within FeMV-1 [16, 18], means that a single PCR assay may fail to detect all circulating strains. Source [26] validated their N-gene TaqMan assay against a panel of FeMV strains, but the assay's performance against FeMV-2 or novel recombinants is unknown. The discovery of FeMV in non-feline hosts, including dogs [20], white-eared opossums [21], and black leopards [22], further complicates the picture, as these hosts may harbor divergent viral variants that escape detection by feline-optimized assays. The use of degenerate primers or multiplex PCR strategies targeting conserved regions of the L gene may improve coverage, but at the cost of reduced sensitivity.

3. Low Viral Loads and Intermittent Shedding: FeMV RNA titers in clinical samples are consistently low, often near the detection limit of even the most sensitive RT-qPCR assays [37, 46]. Source [46] reported that RNA titers were low in all tested urine, blood, and tissue samples, and that IHC was necessary to confirm the presence of viral antigen in tissues with low RNA levels. Furthermore, viral shedding in urine can be intermittent, with some cats shedding virus for up to 360 days [27] while others clear the infection spontaneously [2]. This temporal variability means that a single negative RT-qPCR result does not rule out infection. Longitudinal sampling is essential for accurate diagnosis, but this is often impractical in clinical settings. The use of RT-dPCR, which provides absolute quantification without reliance on standard curves, may improve the detection of low-copy-number targets [31], but its adoption in routine diagnostics remains limited.

4. Lack of a Gold Standard and Discordance Between Assays: The absence of a universally accepted reference standard for FeMV diagnosis creates a circular problem: how can the performance of new assays be validated when no existing assay is definitive? Source [36] compared their i-ELISA to Western blotting and RT-qPCR, but the agreement between these methods was only substantial (κ = 0.664), and 11.8% of ELISA-positive cats were negative by RT-qPCR [36]. Similarly, source [43] found that among 29 FeMV-infected cats, only 14 were both RNA-positive and antibody-positive, while 8 were RNA-positive/antibody-negative and 7 were RNA-negative/antibody-positive. This discordance reflects the dynamic nature of infection, with different phases characterized by different diagnostic profiles. The lack of a gold standard also hampers the assessment of test sensitivity and specificity, as the true infection status of an animal is often unknown.

5. Cell Culture Isolation and Its Limitations: Virus isolation remains the definitive proof of infectious virus, but it is notoriously difficult for FeMV. Source [16] reported that isolation attempts were unsuccessful, although one sample showed a positive RT-qPCR signal until the fourth cell passage. Source [18] successfully isolated FeMV from a German cat, but this required the use of Crandell Rees feline kidney (CRFK) cells and multiple passages. The virus is slow-growing and often produces minimal cytopathic effect, making it challenging to detect. The use of cells expressing the feline SLAMF1 receptor has been shown to improve replication efficiency [29, 13], and this may facilitate future isolation efforts. However, the time and expertise required for virus isolation make it unsuitable for routine diagnostics.

6. Co-infections and Differential Diagnosis: FeMV is frequently detected in cats co-infected with other pathogens, including feline coronavirus, feline leukemia virus, feline immunodeficiency virus, and other paramyxoviruses [20, 27, 15]. Source [20] found that 42.86% of FeMV-positive dogs with respiratory disease were co-infected with other canine respiratory viruses. This high rate of co-infection complicates the attribution of clinical signs to FeMV alone. The clinical presentation of FeMV infection, ranging from acute febrile illness with leukopenia and thrombocytopenia [28] to chronic kidney disease [2], overlaps with many other feline diseases. A comprehensive diagnostic workup that includes testing for common feline pathogens is essential to rule out alternative etiologies. The use of multiplex PCR panels that simultaneously detect FeMV, feline coronavirus, feline herpesvirus, and other agents would be highly beneficial but is not yet widely available.

7. Standardization and Quality Control: There are currently no internationally standardized protocols for FeMV diagnosis. Different laboratories use different primer sets, probe sequences

Clinical Features and Association with Chronic Kidney Disease

The clinical phenotype of feline morbillivirus (FeMV) infection has remained one of the most contentious and enigmatic subjects in contemporary feline medicine since the virus’s discovery in stray cats in Hong Kong in 2012. The initial identification of FeMV was intimately tied to the observation of tubulointerstitial nephritis (TIN), the histopathological hallmark of feline chronic kidney disease (CKD), in infected animals [2, 4]. This association immediately positioned FeMV as a potentially pivotal etiological agent in a disease that represents the leading cause of morbidity and mortality in aged feline populations. However, the decade-and-a-half of subsequent research has revealed a clinical spectrum far more complex than a straightforward causal link, encompassing acute febrile syndromes, subclinical renal injury, persistent viral shedding, and extra-renal manifestations that challenge our understanding of this unique morbillivirus.

The Acute Clinical Syndrome: Beyond the Kidney

While much of the early focus centered on chronic renal pathology, compelling evidence has emerged that FeMV can precipitate an acute, systemic febrile illness, particularly in younger cats. A seminal epidemiological survey employing quantitative reverse transcription PCR (qRT-PCR) on blood samples from cats in Japan detected FeMV RNA in 31.4% (32/102) of animals with suspected acute viral infections [28]. The clinical constellation in these viremic cats was striking and consistent with an acute viral syndrome: fever, leukopenia, thrombocytopenia, and jaundice were prominent findings. Notably, FeMV was not detected in any healthy control cats or in clinically ill cats presenting for routine veterinary care [28]. Necropsy of one fatally infected cat revealed widespread viral dissemination, with FeMV RNA and antigen detected in systemic organs including kidneys, lymph nodes, and spleen, confirming a multisystemic tropism during acute infection [28].

This acute presentation bears hallmarks of classical morbillivirus infections, such as the lymphopenia and fever observed in measles or canine distemper, yet with a fundamentally different clinical trajectory. Experimental infection of specific pathogen-free (SPF) cats has corroborated that FeMV does not induce the severe, acute clinical disease typical of other morbilliviruses [29]. In these controlled studies, infected cats remained largely asymptomatic, yet developed significant renal histopathology, including TIN, underscoring that the most consequential pathology may be subclinical [29]. This dichotomy, between overt acute illness in some naturally infected cats and silent injury in experimental settings, suggests that host factors, viral strain heterogeneity, or concurrent infections may modulate clinical expression.

Defining the Link to Chronic Kidney Disease: Epidemiological Complexities

The association between FeMV infection and CKD has been the subject of intense scrutiny, with studies yielding conflicting results that reflect the multifactorial nature of renal disease and the methodological challenges of studying a widespread, chronically shed pathogen. The initial epidemiological signal was robust: FeMV RNA was detected significantly more frequently in the urine and kidney tissues of cats with renal pathology compared to healthy controls, and this association was strongest in animals with TIN [33, 43]. A landmark histopathological investigation of 38 feline kidney tissue samples demonstrated that FeMV antigen detection was significantly associated with higher tissue injury scores for tubular atrophy, interstitial fibrosis, glomerulosclerosis, and inflammatory cell infiltration, all cardinal features of CKD [33].

Subsequent large-scale cross-sectional studies provided further nuance. In a comprehensive investigation of 223 cats from southern Italy, FeMV RNA was detected in 16.1% of urine samples, and seropositivity was found in 14.5% of animals [27]. Critically, FeMV-positive cats exhibited significantly higher serum creatinine concentrations and lower urine specific gravity, objective markers of renal functional impairment, compared to negative controls [27]. Follow-up of 27 cats, including 13 that were RNA-positive, documented persistent urinary shedding for up to 360 days, demonstrating the capacity for chronic infection [27]. A separate study examining early renal involvement in naturally infected cats revealed that FeMV-positive animals had significantly decreased urine specific gravity and urine creatinine concentrations compared to healthy cats, with urine protein:creatinine ratios (UPC) that were indistinguishable from those of cats with established CKD [39]. Perhaps most strikingly, urine protein sodium-dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 77% of FeMV-infected cats revealed a tubular proteinuria pattern, with decreased uromodulin and increased low-molecular-weight proteins, a signature of early, subclinical tubular damage [39]. Clinical suspicion of CKD was raised in 3 of 14 FeMV-positive cats, suggesting that infection may be associated with renal dysfunction in animals younger than those typically presenting with idiopathic CKD [39].

However, not all evidence has been concordant. A well-designed case-control study in the United Kingdom found no significant difference in FeMV RNA detection between azotemic CKD cats (1/16) and non-azotemic controls (4/24), nor was seroprevalence significantly different between groups [40]. Similarly, a large Brazilian survey of 276 cats found a high paramyxovirus-positive rate (34.7%) but no statistical association between viral RNA shedding in urine and altered kidney function, as assessed by serum biochemistry and urinalysis [15]. These negative findings may reflect geographical differences in viral strains, population-level immunity, or the confounding effect of high background prevalence in regions where infection is endemic.

Histopathological Hallmarks: From Inclusion Bodies to Apoptotic Cascades

The histopathological characterization of FeMV-associated renal disease has provided crucial insights into the pathogenic mechanisms at play. Examination of kidney tissues from FeMV-infected cats has consistently revealed several distinctive features. Eosinophilic intracytoplasmic inclusion bodies (ICIB) within renal tubular epithelial cells represent a pathognomonic finding, observed in cases of natural infection [31, 32]. Ultrastructurally, these inclusions correspond to aggregations of electron-dense viral ribonucleocapsid particles exhibiting the characteristic herringbone morphology of paramyxoviruses [32, 17]. The viral tropism for tubular epithelium is unequivocal: immunohistochemistry (IHC) and in situ hybridization (ISH) consistently localize FeMV antigens and RNA within the cytoplasm and, notably, also the nuclei of tubular epithelial cells, suggesting that viral replication may occur in both cellular compartments [31, 32, 17, 38].

The inflammatory response is dominated by lymphoplasmacytic tubulointerstitial nephritis (TIN), with a prominence of lymphocytes and plasma cells that is consistent with the use of signaling lymphocyte activation molecule F1 (SLAMF1/CD150) as a viral receptor on immune cells [31, 29]. The presence of infiltrating lymphocytes within the renal parenchyma may represent both a host response and a vehicle for viral dissemination, as FeMV has been shown to infect CD4+ and CD20+ lymphocytes [10, 32].

Perhaps the most compelling mechanistic insight relates to the role of apoptosis in FeMV-induced renal injury. A comprehensive analysis of 150 feline kidney tissues, of which 9 (6%) were FeMV genotype 1-positive, demonstrated significantly higher expression of cleaved caspase-3 (cCasp3), a key executioner of apoptotic cell death, in infected versus uninfected kidneys [31]. Furthermore, a strong positive correlation (Spearman’s ρ = 0.8222, p = 0.007) was identified between viral load, quantified by digital PCR, and cCasp3 expression [31]. This caspase-3-dependent apoptotic activity was specific to infected tissues and was observed alongside significantly increased interstitial fibrosis [31]. The absence of a statistically significant association with other apoptotic markers, including BCL-2 and BAX, suggests that FeMV may trigger a selective, caspase-driven apoptotic program rather than a broad dysregulation of cell survival pathways [31]. This finding aligns with observations from experimental infections, where FeMV infection of primary renal epithelial cells induces cytopathic effects consistent with apoptotic cell death [10].

Persistent Infection and the Chronicity Paradigm

A defining characteristic of FeMV that distinguishes it from many other morbilliviruses is its propensity for persistent infection, particularly within the urinary tract. Longitudinal field studies have documented continuous viral shedding in urine for periods exceeding 12 months, even in the presence of robust neutralizing antibody responses [10, 27, 30]. This sustained replication may be facilitated by the virus’s specific adaptation to feline SLAMF1, which is expressed on activated lymphocytes and certain epithelial cells, allowing FeMV to establish a foothold in both immune and renal compartments [29, 13].

The concept of persistent infection is central to the proposed role of FeMV in CKD, as sustained viral replication could drive chronic inflammation and progressive fibrotic remodeling. Experimentally infected cats develop TIN within weeks of infection, and lesion severity correlates with viral load [31, 29]. The observation that viral RNA is frequently detected in kidney tissue from cats without clinical renal disease suggests that infection alone is insufficient to cause CKD; rather, additional cofactors, including age, concurrent retroviral infection with feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV), or host genetic susceptibility, likely determine whether persistent infection progresses to clinical renal failure [27, 14].

Extra-Renal Manifestations and Expanding Host Range

The clinical impact of FeMV extends well beyond the kidney, with accumulating evidence of neurotropism and respiratory involvement that mirrors the systemic nature of morbillivirus infections. A landmark case report documented FeMV RNA in archived brain tissue from a 2-month-old Bengal cat that died of non-suppurative encephalitis in 2011 in Switzerland [48]. In situ hybridization (ISH) confirmed the presence of FeMV RNA in brain sections exhibiting inflammatory lesions, and the viral genome clustered within genotype 1 [48]. This finding of neurotropism is corroborated by in vitro studies demonstrating that FeMV genotype 2 can infect organotypic brain slice cultures, including cells of the cerebrum and cerebellum [10], and by IHC detection of FeMV antigen in astroglia and oligodendroglia of naturally infected cats [32].

The host range of FeMV has also expanded dramatically beyond the domestic cat. The virus has been detected in black leopards (Panthera pardus) with severe azotemia and TIN, where FeMV matrix protein was localized in renal tubular epithelial cells and infiltrating lymphocytes [22]. More remarkably, FeMV infection was documented in dogs with respiratory disease: 12.39% of dogs with respiratory illness were PCR-positive, and viral antigen was confirmed in lung, kidney, lymphoid, and brain tissues of necropsied animals [20]. This cross-species transmission has been further extended to white-eared opossums (Didelphis albiventris) in Brazil, where FeMV RNA was detected in lung and kidney tissues with associated interstitial pneumonia and lymphocytic nephritis, and the virus was isolated in Crandell Rees feline kidney cells [21].

Diagnostic and Clinical Implications

The clinical diagnosis of FeMV infection relies on a combination of molecular and serological methods, each with inherent limitations. Real-time RT-PCR assays targeting conserved regions of the L, N, or P genes have demonstrated high sensitivity and specificity for viral RNA detection in urine, blood, and tissue samples [26, 37, 46]. Urine is the sample of choice, as viral loads are consistently higher in urine compared to blood, reflecting the virus’s renal epitheliotropism [27, 14, 17]. The development of TaqMan-based quantitative RT-PCR assays has enabled detection limits as low as 1.74 × 10⁴ copies/μL, facilitating early infection diagnosis [26]. Serological diagnosis using indirect enzyme-linked immunosorbent assays (i-ELISA) targeting recombinant matrix (M) or nucleocapsid (N) proteins offers a complementary approach, with sensitivities approaching 90.1% and specificities of 75.6% for detecting anti-FeMV antibodies [36]. However, caution is warranted: significant antigenic cross-reactivity exists between the N proteins of FeMV and canine distemper virus (CDV), which can lead to false-positive results in both ELISA and Western blot assays when testing cat plasma samples [1]. Six of 100 cat plasma samples from Japan were double-positive for both anti-FeMV and anti-CDV antibodies, despite no detectable CDV RNA by RT-qPCR, confirming that cross-reactivity is a practical diagnostic concern [1].

The World Organisation for Animal Health (WOAH) recognizes the importance of monitoring emerging viral pathogens in domestic and wild animal populations, and the expanding host range of FeMV, from domestic cats to wild felids, dogs, and marsupials, underscores the need for robust surveillance frameworks. While FeMV is not currently classified as a zoonotic pathogen, and in vitro studies have shown that it does not infect human cell lines [25], its placement within the morbillivirus genus, which includes Measles morbillivirus and Canine morbillivirus, warrants continued vigilance.

The clinical features of FeMV infection thus represent a complex tapestry that belies a simple narrative. The virus can cause acute febrile illness with multisystemic involvement, establish persistent infection with subclinical renal injury, and, under circumstances that remain incompletely defined, contribute to the development of progressive CKD. The histopathological evidence of caspase-3-mediated apoptosis, TIN, and tubular fibrosis provides a mechanistic framework linking viral replication to tissue damage, while the documented neurotropism and cross-species transmission highlight the broader biological significance of this emerging pathogen. The definitive elucidation of FeMV’s role in feline CKD will require long-term prospective studies that integrate molecular diagnostics, serial renal function assessment, and histopathological endpoints in naturally infected populations, ideally coupled with experimental infections that can establish temporal causality. Until such evidence is available, the clinical features of FeMV infection must be interpreted within a framework that acknowledges both the compelling associations and the persistent controversies.

References

[1] Khin STMM, Jafar SM, Ju M, Murakoshi F, Furuya T. Detection of cross-reactivity of antibodies to the N proteins of feline morbillivirus and canine distemper virus in Japanese cat plasma samples.. Journal of Virological Methods. 2025. DOI: https://doi.org/10.1016/j.jviromet.2025.115216

[2] Pennisi M, Belák S, Tasker S, Addie D, Boucraut-Baralon C, Egberink H, et al.. Feline Morbillivirus: Clinical Relevance of a Widespread Endemic Viral Infection of Cats. Viruses. 2023. DOI: https://doi.org/10.3390/v15102087

[3] Luca ED, Sautto G, Crisi P, Lorusso A. Feline Morbillivirus Infection in Domestic Cats: What Have We Learned So Far?. Viruses. 2021. DOI: https://doi.org/10.3390/v13040683

[4] Choi E, Ortega V, Aguilar HC. Feline Morbillivirus, a New Paramyxovirus Possibly Associated with Feline Kidney Disease. Viruses. 2020. DOI: https://doi.org/10.3390/v12050501

[5] Furuya T, Morikawa S, Miyazawa T. Discovery and current research status of feline morbillivirus.. Uirusu. 2016. DOI: https://doi.org/10.2222/jsv.66.147

[6] Seki F, Takeda M. Novel and classical morbilliviruses: Current knowledge of three divergent morbillivirus groups. Microbiology and immunology. 2022. DOI: https://doi.org/10.1111/1348-0421.13030

[7] Nambulli S, Rennick L, Acciardo A, Tilston-Lunel NL, Ho G, Crossland N, et al.. FeMV is a cathepsin-dependent unique morbillivirus infecting the kidneys of domestic cats. Proceedings of the National Academy of Sciences of the United States of America. 2022. DOI: https://doi.org/10.1073/pnas.2209405119

[8] Park E, Suzuki M, Kimura M, Maruyama K, Mizutani H, Saito R, et al.. Identification of a natural recombination in the F and H genes of feline morbillivirus.. Virology. 2014. DOI: https://doi.org/10.1016/j.virol.2014.09.003

[9] Arruda B, Shen H, Zheng Y, Li G. Novel Morbillivirus as Putative Cause of Fetal Death and Encephalitis among Swine. Emerging Infectious Diseases. 2021. DOI: https://doi.org/10.3201/eid2707.203971

[10] A New Genotype of Feline Morbillivirus Infects Primary Cells of the Lung, Kidney, Brain and Peripheral Blood. Viruses. 2019. DOI: https://doi.org/10.3390/v11020146

[11] Yadav A, Rajak KK, Bhatt M, Kumar A, Chakravarti S, Sankar M, et al.. Comparative sequence analysis of morbillivirus receptors and its implication in host range expansion.. Canadian Journal of Microbiology (print). 2019. DOI: https://doi.org/10.1139/cjm-2019-0008

[12] Conceicao C, Willet B, Bailey D. Examining receptor usage by the morbilliviruses: who, or what, is really at risk?. Access Microbiology. 2019. DOI: https://doi.org/10.1099/ACMI.AC2019.PO0337

[13] Tashiro K, Konishi K, Park E, Hyodo A, Seki F, Kitai Y, et al.. Feline morbillivirus elicits robust neutralizing antibodies in domestic cats without cross-neutralizing activities against canonical morbilliviruses.. Journal of General Virology. 2026. DOI: https://doi.org/10.1099/jgv.0.002207

[14] Chaiyasak S, Piewbang C, Rungsipipat A, Techangamsuwan S. Molecular epidemiology and genome analysis of feline morbillivirus in household and shelter cats in Thailand. BMC Veterinary Research. 2020. DOI: https://doi.org/10.1186/s12917-020-02467-4

[15] Darold GM, Alfieri A, Júnior JPA, Cruz TFd, Bertti KMdLB, Silva GCPd, et al.. High genetic diversity of paramyxoviruses infecting domestic cats in Western Brazil.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13950

[16] Muratore E, Cerutti F, Colombino E, Biasibetti E, Caruso C, Brovida C, et al.. Feline morbillivirus in northwestern Italy: first detection of genotype 1-B. Journal of feline medicine and surgery. 2020. DOI: https://doi.org/10.1177/1098612X20969360

[17] Chaiyasak S. Epidemiological surveillance of feline morbillivirus infection in the aspects of polymerase chain reaction, indirect elisa and immunohistochemistry. . None. DOI: https://doi.org/10.58837/chula.the.2019.536

[18] Sieg M, Vahlenkamp A, Baums C, Vahlenkamp T. First Complete Genome Sequence of a Feline Morbillivirus Isolate from Germany. Genome Announcements. 2018. DOI: https://doi.org/10.1128/genomeA.00244-18

[19] Busch J, Sacristán I, Cevidanes A, Millán J, Vahlenkamp T, Napolitano C, et al.. High seroprevalence of feline morbilliviruses in free-roaming domestic cats in Chile. Archives of Virology. 2020. DOI: https://doi.org/10.1007/s00705-020-04882-2

[20] Piewbang C, Wardhani SW, Dankaona W, Yostawonkul J, Boonrungsiman S, Surachetpong W, et al.. Feline morbillivirus-1 in dogs with respiratory diseases.. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14278

[21] Lavorente FLP, Matos AMRNd, Lorenzetti E, Oliveira MV, Pinto-Ferreira F, Michelazzo MZ, et al.. First detection of Feline morbillivirus infection in white-eared opossums (Didelphis albiventris, Lund, 1840), a non-feline host.. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14109

[22] Piewbang C, Chaiyasak S, Kongmakee P, Sanannu S, Khotapat P, Ratthanophart J, et al.. Feline Morbillivirus Infection Associated With Tubulointerstitial Nephritis in Black Leopards (Panthera pardus). Veterinary Pathology-Supplement. 2020. DOI: https://doi.org/10.1177/0300985820948820

[23] Sieg M, Sacristán I, Busch J, Terio K, Cabello J, Hidalgo-Hermoso E, et al.. Identification of Novel Feline Paramyxoviruses in Guignas (Leopardus guigna) from Chile. Viruses. 2020. DOI: https://doi.org/10.3390/v12121397

[24] Terio K, Craft M. Canine Distemper Virus (CDV) in Another Big Cat: Should CDV Be Renamed Carnivore Distemper Virus?. mBio. 2013. DOI: https://doi.org/10.1128/mBio.00702-13

[25] Sakaguchi S, Koide R, Miyazawa T. In vitro host range of feline morbillivirus. Journal of Veterinary Medical Science. 2015. DOI: https://doi.org/10.1292/jvms.15-0213

[26] Makhtar ST, Tan SW, Nasruddin N, Aziz NAA, Omar A, Mustaffa-Kamal F. Development of TaqMan-based real-time RT-PCR assay based on N gene for the quantitative detection of feline morbillivirus. BMC Veterinary Research. 2020. DOI: https://doi.org/10.1186/s12917-021-02837-6

[27] Donato G, Masucci M, Luca ED, Alibrandi A, Majo MD, Berjaoui S, et al.. Feline Morbillivirus in Southern Italy: Epidemiology, Clinico-Pathological Features and Phylogenetic Analysis in Cats. Viruses. 2021. DOI: https://doi.org/10.3390/v13081449

[28] Ito G, Tabata S, Matsuu A, Hatai H, Goto-Koshino Y, Kuramoto T, et al.. Detection of feline morbillivirus in cats with symptoms of acute febrile infection. Veterinary research communications. 2023. DOI: https://doi.org/10.1007/s11259-023-10214-x

[29] Nikolin V, Doi LHS, Sieg M, Busch J, Böttcher D, Tedeschi L, et al.. In Vitro Growth, Receptor Usage and Pathogenesis of Feline Morbillivirus in the Natural Host. Viruses. 2022. DOI: https://doi.org/10.3390/v14071503

[30] Sharp C, Nambulli S, Acciardo A, Rennick L, Drexler J, Rima B, et al.. Chronic Infection of Domestic Cats with Feline Morbillivirus, United States. Emerging Infectious Diseases. 2016. DOI: https://doi.org/10.3201/eid2204.151921

[31] Zahro A, Poonsin P, Sieg M, Vahlenkamp T, Piewbang C, Techangamsuwan S. Pathological alteration and caspase-dependent activity of feline kidneys in natural infection of feline morbillivirus. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-04953-z

[32] Chaiyasak S, Piewbang C, Yostawonkul J, Boonrungsiman S, Kasantikul T, Rungsipipat A, et al.. Renal epitheliotropism of feline morbillivirus in two cats. Veterinary Pathology-Supplement. 2021. DOI: https://doi.org/10.1177/03009858211045441

[33] Sutummaporn K, Suzuki K, Machida N, Mizutani T, Park E, Morikawa S, et al.. Association of feline morbillivirus infection with defined pathological changes in cat kidney tissues.. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2018.11.005

[34] Koide R, Sakaguchi S, Miyazawa T. Basic biological characterization of feline morbillivirus. Journal of Veterinary Medical Science. 2015. DOI: https://doi.org/10.1292/jvms.14-0623

[35] Makhtar ST, Tan SW, Omar A, Mustaffa-Kamal F. Sequencing Analysis of Partial N gene of Feline Morbillivirus from Malaysia. Pertanika Journal of Tropical Agricultural Science. 2022. DOI: https://doi.org/10.47836/pjtas.45.1.20

[36] Chaiyasak S, Piewbang C, Ratthanophart J, Techakriengkrai N, Rattanaporn K, Techangamsuwan S. Detection of Antibodies against Feline Morbillivirus by Recombinant Matrix Enzyme-Linked Immunosorbent Assay. Viruses. 2024. DOI: https://doi.org/10.3390/v16081339

[37] Furuya T, Wachi A, Sassa Y, Omatsu T, Nagai M, Fukushima R, et al.. Quantitative PCR detection of feline morbillivirus in cat urine samples. Journal of Veterinary Medical Science. 2015. DOI: https://doi.org/10.1292/jvms.15-0112

[38] Zahro A. Associations of feline paramyxoviruses with pathological lesions in cat kidneys. . None. DOI: https://doi.org/10.58837/chula.the.2022.370

[39] Crisi P, Dondi F, Luca ED, Tommaso MD, Vasylyeva K, Ferlizza E, et al.. Early Renal Involvement in Cats with Natural Feline Morbillivirus Infection. Animals. 2020. DOI: https://doi.org/10.3390/ani10050828

[40] McCallum K, Stubbs SCB, Hope N, Mickleburgh I, Dight D, Tiley L, et al.. Detection and seroprevalence of morbillivirus and other paramyxoviruses in geriatric cats with and without evidence of azotemic chronic kidney disease. Journal of Veterinary Internal Medicine. 2018. DOI: https://doi.org/10.1111/jvim.15097

[41] Luca ED, Crisi P, Marcacci M, Malatesta D, Sabatino DD, Cito F, et al.. Epidemiology, pathological aspects and genome heterogeneity of feline morbillivirus in Italy. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2019.108484

[42] Mendes F, Delgado L, Escobar M, Rodrigues AC, Fernandes T, Brilhante-Simões PM, et al.. Clinical/research abstracts accepted for presentation at ISFM Congress 2018. Journal of feline medicine and surgery. 2018. DOI: https://doi.org/10.1177/1098612X18791875

[43] Park E, Suzuki M, Kimura M, Mizutani H, Saito R, Kubota N, et al.. Epidemiological and pathological study of feline morbillivirus infection in domestic cats in Japan. BMC Veterinary Research. 2016. DOI: https://doi.org/10.1186/s12917-016-0853-y

[44] Beatty JA, Sharp C, Duprex WP, Munday J. Novel feline viruses: Emerging significance of gammaherpesvirus and morbillivirus infections. Journal of feline medicine and surgery. 2018. DOI: https://doi.org/10.1177/1098612x18808102

[45] Isa NHM, Selvarajah GT, Khor KH, Tan SW, Manoraj H, Omar NH, et al.. Molecular detection and characterisation of feline morbillivirus in domestic cats in Malaysia. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2019.08.005

[46] Luca ED, Crisi P, Domenico MD, Malatesta D, Vincifori G, Tommaso MD, et al.. A real-time RT-PCR assay for molecular identification and quantitation of feline morbillivirus RNA from biological specimens.. Journal of Virological Methods. 2018. DOI: https://doi.org/10.1016/j.jviromet.2018.05.002

[47] Koide R, Sakaguchi S, Ogawa M, Miyazawa T. Rapid detection of feline morbillivirus by a reverse transcription loop-mediated isothermal amplification. Journal of Veterinary Medical Science. 2015. DOI: https://doi.org/10.1292/jvms.15-0239

[48] Dawson KLD, Wildi N, Cavalli M, Rubbenstroth D, Oevermann A, Seuberlich T. Feline morbillivirus infection associated with fatal encephalitis in a Bengal cat. Journal of Veterinary Internal Medicine. 2023. DOI: https://doi.org/10.1111/jvim.16916

[49] Momoi Y, Matsuu A. Detection of severe fever with thrombocytopenia syndrome virus and other viruses in cats via unbiased next-generation sequencing. Journal of Veterinary Diagnostic Investigation. 2020. DOI: https://doi.org/10.1177/1040638720967506

[50] Stranieri A, Lauzi S, Dallari A, Gelain M, Bonsembiante F, Ferro S, et al.. Feline morbillivirus in Northern Italy: prevalence in urine and kidneys with and without renal disease. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2019.04.027

[51] Marcacci M, Luca ED, Zaccaria G, Tommaso MD, Mangone I, Aste G, et al.. Genome characterization of feline morbillivirus from Italy. Journal of Virological Methods. 2016. DOI: https://doi.org/10.1016/j.jviromet.2016.05.002 *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.